ZA200301947B - Complexes containing perfluoroalkyl with polar radicals, method for the production and use thereof. - Google Patents
Complexes containing perfluoroalkyl with polar radicals, method for the production and use thereof. Download PDFInfo
- Publication number
- ZA200301947B ZA200301947B ZA200301947A ZA200301947A ZA200301947B ZA 200301947 B ZA200301947 B ZA 200301947B ZA 200301947 A ZA200301947 A ZA 200301947A ZA 200301947 A ZA200301947 A ZA 200301947A ZA 200301947 B ZA200301947 B ZA 200301947B
- Authority
- ZA
- South Africa
- Prior art keywords
- mmol
- general formula
- radical
- metal complexes
- contrast medium
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 32
- 238000004519 manufacturing process Methods 0.000 title claims description 22
- 125000005010 perfluoroalkyl group Chemical group 0.000 title claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 129
- 239000002872 contrast media Substances 0.000 claims description 59
- 229910052751 metal Inorganic materials 0.000 claims description 37
- 239000002184 metal Substances 0.000 claims description 37
- 238000003384 imaging method Methods 0.000 claims description 30
- 229940039231 contrast media Drugs 0.000 claims description 29
- 238000003745 diagnosis Methods 0.000 claims description 29
- 229910021645 metal ion Inorganic materials 0.000 claims description 24
- 239000003795 chemical substances by application Substances 0.000 claims description 21
- 206010028980 Neoplasm Diseases 0.000 claims description 20
- 229910052731 fluorine Inorganic materials 0.000 claims description 20
- 206010061216 Infarction Diseases 0.000 claims description 19
- 239000004472 Lysine Substances 0.000 claims description 18
- 230000007574 infarction Effects 0.000 claims description 18
- 239000011737 fluorine Substances 0.000 claims description 17
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 150000001413 amino acids Chemical class 0.000 claims description 12
- 150000004696 coordination complex Chemical class 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 12
- 206010028851 Necrosis Diseases 0.000 claims description 11
- 230000017074 necrotic cell death Effects 0.000 claims description 11
- 150000001735 carboxylic acids Chemical class 0.000 claims description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 238000001959 radiotherapy Methods 0.000 claims description 9
- 125000006239 protecting group Chemical group 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 238000001990 intravenous administration Methods 0.000 claims description 7
- OVBPIULPVIDEAO-LBPRGKRZSA-N Folic acid Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 6
- 125000001153 fluoro group Chemical group F* 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 5
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 5
- 239000000654 additive Substances 0.000 claims description 5
- 150000001768 cations Chemical group 0.000 claims description 5
- 229960000304 folic acid Drugs 0.000 claims description 5
- 235000019152 folic acid Nutrition 0.000 claims description 5
- 239000011724 folic acid Substances 0.000 claims description 5
- 150000007530 organic bases Chemical class 0.000 claims description 5
- 239000008177 pharmaceutical agent Substances 0.000 claims description 5
- 229910052770 Uranium Inorganic materials 0.000 claims description 4
- 230000002378 acidificating effect Effects 0.000 claims description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 4
- 238000003776 cleavage reaction Methods 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 150000007529 inorganic bases Chemical class 0.000 claims description 4
- 239000011630 iodine Chemical group 0.000 claims description 4
- 229910052740 iodine Inorganic materials 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 4
- 230000007017 scission Effects 0.000 claims description 4
- 101000913968 Ipomoea purpurea Chalcone synthase C Proteins 0.000 claims description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 3
- 101000907988 Petunia hybrida Chalcone-flavanone isomerase C Proteins 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical group II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 3
- 210000004324 lymphatic system Anatomy 0.000 claims description 3
- 230000002792 vascular Effects 0.000 claims description 3
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical group ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims description 2
- 229910006069 SO3H Inorganic materials 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 239000000460 chlorine Chemical group 0.000 claims description 2
- 238000005859 coupling reaction Methods 0.000 claims description 2
- 229910044991 metal oxide Inorganic materials 0.000 claims description 2
- 150000004706 metal oxides Chemical class 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 2
- 125000004434 sulfur atom Chemical group 0.000 claims description 2
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 claims 1
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims 1
- 101150065749 Churc1 gene Proteins 0.000 claims 1
- 102100038239 Protein Churchill Human genes 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 159
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 93
- 238000004458 analytical method Methods 0.000 description 82
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 81
- 239000007787 solid Substances 0.000 description 79
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 75
- 239000000243 solution Substances 0.000 description 69
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 63
- 239000002904 solvent Substances 0.000 description 49
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 46
- 239000000741 silica gel Substances 0.000 description 46
- 229910002027 silica gel Inorganic materials 0.000 description 46
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 42
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 42
- 239000007983 Tris buffer Substances 0.000 description 37
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 36
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 36
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 36
- 239000000126 substance Substances 0.000 description 36
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- 239000003054 catalyst Substances 0.000 description 31
- 239000000706 filtrate Substances 0.000 description 29
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 27
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 26
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 23
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- 210000001519 tissue Anatomy 0.000 description 20
- GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 description 18
- 210000001165 lymph node Anatomy 0.000 description 18
- 239000003921 oil Substances 0.000 description 18
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 18
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 17
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- 238000004587 chromatography analysis Methods 0.000 description 15
- 150000002500 ions Chemical class 0.000 description 15
- -1 neodymium(III) ion Chemical class 0.000 description 15
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 14
- 229910052763 palladium Inorganic materials 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 11
- 235000002639 sodium chloride Nutrition 0.000 description 11
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 239000012074 organic phase Substances 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- 238000005481 NMR spectroscopy Methods 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 8
- 235000019341 magnesium sulphate Nutrition 0.000 description 8
- 239000011572 manganese Substances 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000004202 carbamide Substances 0.000 description 7
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 6
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000002751 lymph Anatomy 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000003325 tomography Methods 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 208000010125 myocardial infarction Diseases 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000005298 paramagnetic effect Effects 0.000 description 5
- 150000004032 porphyrins Chemical class 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 238000004904 shortening Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 4
- 229910052688 Gadolinium Inorganic materials 0.000 description 4
- 102000008100 Human Serum Albumin Human genes 0.000 description 4
- 108091006905 Human Serum Albumin Proteins 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 4
- 229940075613 gadolinium oxide Drugs 0.000 description 4
- 229910001938 gadolinium oxide Inorganic materials 0.000 description 4
- CMIHHWBVHJVIGI-UHFFFAOYSA-N gadolinium(iii) oxide Chemical compound [O-2].[O-2].[O-2].[Gd+3].[Gd+3] CMIHHWBVHJVIGI-UHFFFAOYSA-N 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 229910052748 manganese Inorganic materials 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 239000012465 retentate Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- 238000012800 visualization Methods 0.000 description 4
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 3
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 3
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 229910052777 Praseodymium Inorganic materials 0.000 description 3
- STSCVKRWJPWALQ-UHFFFAOYSA-N TRIFLUOROACETIC ACID ETHYL ESTER Chemical compound CCOC(=O)C(F)(F)F STSCVKRWJPWALQ-UHFFFAOYSA-N 0.000 description 3
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N Valeric acid Natural products CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000000032 diagnostic agent Substances 0.000 description 3
- 229940039227 diagnostic agent Drugs 0.000 description 3
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 150000002221 fluorine Chemical class 0.000 description 3
- SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000001926 lymphatic effect Effects 0.000 description 3
- 150000002678 macrocyclic compounds Chemical class 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000001338 necrotic effect Effects 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- CKGCFBNYQJDIGS-LBPRGKRZSA-N (2s)-2-azaniumyl-6-(phenylmethoxycarbonylamino)hexanoate Chemical compound [O-]C(=O)[C@@H]([NH3+])CCCCNC(=O)OCC1=CC=CC=C1 CKGCFBNYQJDIGS-LBPRGKRZSA-N 0.000 description 2
- OSBDRCULGZZSPQ-LBPRGKRZSA-N (2s)-6-(phenylmethoxycarbonylamino)-2-[(2,2,2-trifluoroacetyl)amino]hexanoic acid Chemical compound FC(F)(F)C(=O)N[C@H](C(=O)O)CCCCNC(=O)OCC1=CC=CC=C1 OSBDRCULGZZSPQ-LBPRGKRZSA-N 0.000 description 2
- FSSPGSAQUIYDCN-UHFFFAOYSA-N 1,3-Propane sultone Chemical compound O=S1(=O)CCCO1 FSSPGSAQUIYDCN-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- DDTZAHIJJCRGFT-UHFFFAOYSA-N 2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]acetic acid Chemical compound COCCOCCOCCOCCOCC(O)=O DDTZAHIJJCRGFT-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical group NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 2
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 2
- 206010027459 Metastases to lymph nodes Diseases 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 238000009529 body temperature measurement Methods 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- PBHVCRIXMXQXPD-UHFFFAOYSA-N chembl2369102 Chemical compound C1=CC(S(=O)(=O)O)=CC=C1C(C1=CC=C(N1)C(C=1C=CC(=CC=1)S(O)(=O)=O)=C1C=CC(=N1)C(C=1C=CC(=CC=1)S(O)(=O)=O)=C1C=CC(N1)=C1C=2C=CC(=CC=2)S(O)(=O)=O)=C2N=C1C=C2 PBHVCRIXMXQXPD-UHFFFAOYSA-N 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000010612 desalination reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- FVIZARNDLVOMSU-UHFFFAOYSA-N ginsenoside K Natural products C1CC(C2(CCC3C(C)(C)C(O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O FVIZARNDLVOMSU-UHFFFAOYSA-N 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 230000005291 magnetic effect Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 229960003330 pentetic acid Drugs 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000002600 positron emission tomography Methods 0.000 description 2
- KZKCOVQRXJUGDG-UHFFFAOYSA-N praseodymium Chemical compound [Pr][Pr] KZKCOVQRXJUGDG-UHFFFAOYSA-N 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 229910052761 rare earth metal Inorganic materials 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 2
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical class FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- AWSFICBXMUKWSK-UHFFFAOYSA-N ytterbium(3+) Chemical compound [Yb+3] AWSFICBXMUKWSK-UHFFFAOYSA-N 0.000 description 2
- CUGDYSSBTWBKII-LXGUWJNJSA-N (2r,3r,4r,5s)-6-(dimethylamino)hexane-1,2,3,4,5-pentol Chemical compound CN(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO CUGDYSSBTWBKII-LXGUWJNJSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- BGGHCRNCRWQABU-JTQLQIEISA-N (2s)-2-amino-5-oxo-5-phenylmethoxypentanoic acid Chemical compound OC(=O)[C@@H](N)CCC(=O)OCC1=CC=CC=C1 BGGHCRNCRWQABU-JTQLQIEISA-N 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- UVWPNDVAQBNQBG-UHFFFAOYSA-N 1,1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,9-icosafluorononane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F UVWPNDVAQBNQBG-UHFFFAOYSA-N 0.000 description 1
- DXMXODXDVBZUAU-UHFFFAOYSA-N 1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-octadecafluorocyclononane Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C1(F)F DXMXODXDVBZUAU-UHFFFAOYSA-N 0.000 description 1
- SSJZVUZQISSZSP-UHFFFAOYSA-N 1,2,2,3,3,5,5,6,6-nonafluoro-4-(1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctylsulfonyl)piperazine Chemical compound FN1C(F)(F)C(F)(F)N(S(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F)C(F)(F)C1(F)F SSJZVUZQISSZSP-UHFFFAOYSA-N 0.000 description 1
- KPZGRMZPZLOPBS-UHFFFAOYSA-N 1,3-dichloro-2,2-bis(chloromethyl)propane Chemical compound ClCC(CCl)(CCl)CCl KPZGRMZPZLOPBS-UHFFFAOYSA-N 0.000 description 1
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 1
- QBPPRVHXOZRESW-UHFFFAOYSA-N 1,4,7,10-tetraazacyclododecane Chemical compound C1CNCCNCCNCCN1 QBPPRVHXOZRESW-UHFFFAOYSA-N 0.000 description 1
- AWNXKZVIZARMME-UHFFFAOYSA-N 1-[[5-[2-[(2-chloropyridin-4-yl)amino]pyrimidin-4-yl]-4-(cyclopropylmethyl)pyrimidin-2-yl]amino]-2-methylpropan-2-ol Chemical compound N=1C(NCC(C)(O)C)=NC=C(C=2N=C(NC=3C=C(Cl)N=CC=3)N=CC=2)C=1CC1CC1 AWNXKZVIZARMME-UHFFFAOYSA-N 0.000 description 1
- UVPOMFMAVHWVCV-UHFFFAOYSA-N 1-hexoxypyrrolidine-2,5-dione Chemical compound CCCCCCON1C(=O)CCC1=O UVPOMFMAVHWVCV-UHFFFAOYSA-N 0.000 description 1
- FBDGHDWQYGJZQU-UHFFFAOYSA-N 2,3-bis(phenylmethoxy)propan-1-ol Chemical compound C=1C=CC=CC=1COC(CO)COCC1=CC=CC=C1 FBDGHDWQYGJZQU-UHFFFAOYSA-N 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- NOYNSTBGYRYFEE-UHFFFAOYSA-N 2-[2,3-bis(phenylmethoxy)propoxy]acetic acid Chemical compound C=1C=CC=CC=1COC(COCC(=O)O)COCC1=CC=CC=C1 NOYNSTBGYRYFEE-UHFFFAOYSA-N 0.000 description 1
- IBCKLSQYIMSZQO-UHFFFAOYSA-N 2-[2-(carboxymethylamino)ethylamino]-4-ethoxy-4-oxobutanoic acid Chemical compound CCOC(=O)CC(C(O)=O)NCCNCC(O)=O IBCKLSQYIMSZQO-UHFFFAOYSA-N 0.000 description 1
- HJFVQTISUBPKCS-UHFFFAOYSA-N 2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]acetyl chloride Chemical compound COCCOCCOCCOCC(Cl)=O HJFVQTISUBPKCS-UHFFFAOYSA-N 0.000 description 1
- WTNMWCJVEAIMLV-UHFFFAOYSA-N 2-[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]propanoylamino]acetic acid Chemical compound OC(=O)CNC(=O)C(C)N1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WTNMWCJVEAIMLV-UHFFFAOYSA-N 0.000 description 1
- CVZUFVWWUHUKHS-UHFFFAOYSA-N 2-[[2-[2-(2-carboxyethylamino)ethylamino]ethylamino]methyl]-4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoic acid Chemical compound CC(C)(C)OC(=O)CC(C(O)=O)CNCCNCCNCCC(O)=O CVZUFVWWUHUKHS-UHFFFAOYSA-N 0.000 description 1
- XKZJHMYMBVDBRU-UHFFFAOYSA-N 2-[carboxymethyl-[2-(2,6-dioxomorpholin-4-yl)ethyl]amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)CCN1CC(=O)OC(=O)C1 XKZJHMYMBVDBRU-UHFFFAOYSA-N 0.000 description 1
- YJVXEQJVAOGXKM-UHFFFAOYSA-N 2-ethoxy-2h-quinoline-1-carboxylic acid Chemical compound C1=CC=C2N(C(O)=O)C(OCC)C=CC2=C1 YJVXEQJVAOGXKM-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- JJUBFBTUBACDHW-UHFFFAOYSA-N 3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluoro-1-decanol Chemical compound OCCC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F JJUBFBTUBACDHW-UHFFFAOYSA-N 0.000 description 1
- NNOHXABAQAGKRZ-UHFFFAOYSA-N 3,5-dinitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC(C(Cl)=O)=CC([N+]([O-])=O)=C1 NNOHXABAQAGKRZ-UHFFFAOYSA-N 0.000 description 1
- PZASAAIJIFDWSB-CKPDSHCKSA-N 8-[(1S)-1-[8-(trifluoromethyl)-7-[4-(trifluoromethyl)cyclohexyl]oxynaphthalen-2-yl]ethyl]-8-azabicyclo[3.2.1]octane-3-carboxylic acid Chemical compound FC(F)(F)C=1C2=CC([C@@H](N3C4CCC3CC(C4)C(O)=O)C)=CC=C2C=CC=1OC1CCC(C(F)(F)F)CC1 PZASAAIJIFDWSB-CKPDSHCKSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- MCZOCLQYOASCDQ-UHFFFAOYSA-N CC(C)(C)OC(=O)CN(CCC(O)=O)CCN(CC(O)=O)CCN(CCC(O)=O)CC(=O)OC(C)(C)C Chemical compound CC(C)(C)OC(=O)CN(CCC(O)=O)CCN(CC(O)=O)CCN(CCC(O)=O)CC(=O)OC(C)(C)C MCZOCLQYOASCDQ-UHFFFAOYSA-N 0.000 description 1
- 101100028482 Caenorhabditis elegans pal-1 gene Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229910001436 Cr3+ Inorganic materials 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229910052692 Dysprosium Inorganic materials 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- HBBGRARXTFLTSG-UHFFFAOYSA-N Lithium ion Chemical compound [Li+] HBBGRARXTFLTSG-UHFFFAOYSA-N 0.000 description 1
- 241001417539 Liza Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- PQBAWAQIRZIWIV-UHFFFAOYSA-N N-methylpyridinium Chemical compound C[N+]1=CC=CC=C1 PQBAWAQIRZIWIV-UHFFFAOYSA-N 0.000 description 1
- 229910052779 Neodymium Inorganic materials 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 229910052772 Samarium Inorganic materials 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- LVWBEIYNTHOOKW-UHFFFAOYSA-N acetic acid;2-[4-(2,3-diaminopropyl)phenoxy]acetic acid Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.NCC(N)CC1=CC=C(OCC(O)=O)C=C1 LVWBEIYNTHOOKW-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000008331 benzenesulfonamides Chemical class 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- KQNZLOUWXSAZGD-UHFFFAOYSA-N benzylperoxymethylbenzene Chemical compound C=1C=CC=CC=1COOCC1=CC=CC=C1 KQNZLOUWXSAZGD-UHFFFAOYSA-N 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- WEQAYVWKMWHEJO-UHFFFAOYSA-N chlormezanone Chemical compound O=S1(=O)CCC(=O)N(C)C1C1=CC=C(Cl)C=C1 WEQAYVWKMWHEJO-UHFFFAOYSA-N 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
- 229940106681 chloroacetic acid Drugs 0.000 description 1
- BFGKITSFLPAWGI-UHFFFAOYSA-N chromium(3+) Chemical compound [Cr+3] BFGKITSFLPAWGI-UHFFFAOYSA-N 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- XLJKHNWPARRRJB-UHFFFAOYSA-N cobalt(2+) Chemical compound [Co+2] XLJKHNWPARRRJB-UHFFFAOYSA-N 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 150000001923 cyclic compounds Chemical class 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- IOIFRTZBJMZZFO-UHFFFAOYSA-N dysprosium(3+) Chemical compound [Dy+3] IOIFRTZBJMZZFO-UHFFFAOYSA-N 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- JHFPQYFEJICGKC-UHFFFAOYSA-N erbium(3+) Chemical compound [Er+3] JHFPQYFEJICGKC-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 150000002251 gadolinium compounds Chemical class 0.000 description 1
- RJOJUSXNYCILHH-UHFFFAOYSA-N gadolinium(3+) Chemical compound [Gd+3] RJOJUSXNYCILHH-UHFFFAOYSA-N 0.000 description 1
- 229910052733 gallium Inorganic materials 0.000 description 1
- 125000000267 glycino group Chemical group [H]N([*])C([H])([H])C(=O)O[H] 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- HCDGVLDPFQMKDK-UHFFFAOYSA-N hexafluoropropylene Chemical group FC(F)=C(F)C(F)(F)F HCDGVLDPFQMKDK-UHFFFAOYSA-N 0.000 description 1
- SCKNFLZJSOHWIV-UHFFFAOYSA-N holmium(3+) Chemical compound [Ho+3] SCKNFLZJSOHWIV-UHFFFAOYSA-N 0.000 description 1
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical compound O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000009399 inbreeding Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910001411 inorganic cation Inorganic materials 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229910052746 lanthanum Inorganic materials 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229910001416 lithium ion Inorganic materials 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- IPFASKMZBDWRNG-UHFFFAOYSA-N manganese 5,10,15,20-tetraphenyl-21,23-dihydroporphyrin Chemical compound [Mn].c1cc2nc1c(-c1ccccc1)c1ccc([nH]1)c(-c1ccccc1)c1ccc(n1)c(-c1ccccc1)c1ccc([nH]1)c2-c1ccccc1 IPFASKMZBDWRNG-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000011177 media preparation Methods 0.000 description 1
- MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 1
- AKZFRMNXBLFDNN-UHFFFAOYSA-K meso-tetrakis(n-methyl-4-pyridyl)porphine tetrakis(p-toluenesulfonate) Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1.C1=C[N+](C)=CC=C1C(C=1C=CC(N=1)=C(C=1C=C[N+](C)=CC=1)C1=CC=C(N1)C(C=1C=C[N+](C)=CC=1)=C1C=CC(N1)=C1C=2C=C[N+](C)=CC=2)=C2N=C1C=C2 AKZFRMNXBLFDNN-UHFFFAOYSA-K 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- XGDZEDRBLVIUMX-UHFFFAOYSA-N methyl 2-(4-hydroxyphenyl)acetate Chemical compound COC(=O)CC1=CC=C(O)C=C1 XGDZEDRBLVIUMX-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002159 nanocrystal Substances 0.000 description 1
- QEFYFXOXNSNQGX-UHFFFAOYSA-N neodymium atom Chemical compound [Nd] QEFYFXOXNSNQGX-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000005414 paramagnetic center Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- WTWWXOGTJWMJHI-UHFFFAOYSA-N perflubron Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br WTWWXOGTJWMJHI-UHFFFAOYSA-N 0.000 description 1
- 229960001217 perflubron Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- 231100000434 photosensitization Toxicity 0.000 description 1
- 108700020395 polylysine-(Gd-DTPA) Proteins 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000000637 radiosensitizating effect Effects 0.000 description 1
- 150000002910 rare earth metals Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229910052702 rhenium Inorganic materials 0.000 description 1
- WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- GVGXPXPGZLUONX-UHFFFAOYSA-N samarium Chemical compound [Sm][Sm][Sm][Sm][Sm][Sm][Sm][Sm][Sm][Sm][Sm][Sm][Sm][Sm] GVGXPXPGZLUONX-UHFFFAOYSA-N 0.000 description 1
- DOSGOCSVHPUUIA-UHFFFAOYSA-N samarium(3+) Chemical compound [Sm+3] DOSGOCSVHPUUIA-UHFFFAOYSA-N 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000003579 shift reagent Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000005654 stationary process Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229910052713 technetium Inorganic materials 0.000 description 1
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 1
- HKCRVXUAKWXBLE-UHFFFAOYSA-N terbium(3+) Chemical compound [Tb+3] HKCRVXUAKWXBLE-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 230000019432 tissue death Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- KAKQVSNHTBLJCH-UHFFFAOYSA-N trifluoromethanesulfonimidic acid Chemical class NS(=O)(=O)C(F)(F)F KAKQVSNHTBLJCH-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- ORZHVTYKPFFVMG-UHFFFAOYSA-N xylenol orange Chemical compound OC(=O)CN(CC(O)=O)CC1=C(O)C(C)=CC(C2(C3=CC=CC=C3S(=O)(=O)O2)C=2C=C(CN(CC(O)=O)CC(O)=O)C(O)=C(C)C=2)=C1 ORZHVTYKPFFVMG-UHFFFAOYSA-N 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F19/00—Metal compounds according to more than one of main groups C07F1/00 - C07F17/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
- A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
- A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Radiology & Medical Imaging (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
® wo rs PCT/EP01/08500
Perfluoroalkyl-Containing Complexes with Polar Radicals,
Process for their Production and their Use
The invention relates to the subjects that are characterized in the claims, namely perfluoroalkyl-containing metal complexes with polar radicals of general formula I, process for their production and their use in NMR diagnosis and x-ray diagnosis, radiodiagnosis and radiotherapy, in MRT-lymphography and as blood-pool agents. The compounds according to the invention are quite especially suitable for intravenous lymphography, for tumor diagnosis and for infarction and necrosis imaging.
In nuclear magnetic resonance, the element fluorine is second in importance to the element hydrogen. 1) Fluorine has a high sensitivity of 83% of that of hydrogen. 2) Fluorine has only one NMR-active isotope. 3) Fluorine has a resonance frequency that is similar to hydrogen -- fluorine and hydrogen can be measured with the same system. 4) Fluorine is biologically inert. 5) Fluorine does not occur in biological material (exception: teeth) and can therefore be used as a probe or contrast medium against a background that is free of interfering signals.
The effect of these properties is that fluorine occupies a broad space in diagnostic patent literature with magnetic nuclear resonance as a basis: fluorine-19-imaging, functional diagnosis, spectroscopy.
US Patent 4,639,364 (Mallinckrodt) thus proposes trifluoromethanesulfonamides as
2 8200371947 ® on media for fluorine-19-imaging:
CFiSO-NH:
CF3SONH-CH2-(CHOH)4-CH20H
German Patent DE 4203234 (Max-Planck-Gesellschaft). in which an aniline derivative is proposed:
CF, 7 ON oF [rico
CF! — also relates to fluorine-19-imaging.
Fluorine-19-imaging is the subject of Application WO 93/07907 (Mallinckrodt), in which phenyl derivatives are also claimed as contrast media:
HO OH
0 Dad
CF, CF, HO goa ¢ oO N] H noe —! S—cop Nn Scr, ps / , ns
J or! CF, HO CF, N © pp
HO OH
For fluorine-19-imaging, compounds of considerably simpler structure are also claimed.
Thus, Patent US 4,586,511 (Children's Hospital Medical Center) mentions perfluorooctylbromide
CF3(CF2)7-Br,
European Patent EP 307863 (Air Products) mentions perfluoro-1 5-crown-5-ether
] ; @d003/1947
F i | F
F 0 No F
F TT ~~. " > Lt
F No 0” F
I=
ED eS
F
F
F FF and U.S. Patent US 4,588,279 (University of Cincinnati, Children's Hospital Research
Foundation) mentions perfluorocarbon compounds such as perfluorocyclononane or -octane, perfluorinated ethers such as tetrahydrofuran
Ne = = F
FO OF or diethers such as perfluoropropylene glycol-diether
CF, Fs
F——o—cr,cr,cr—o—{—F
CF, CF,
The compounds that are mentioned in Application WO 94/22368 (Molecular
Biosystems), e.g.,
O-CO~(CH,)-R
CHa{CH,)y-CH=CH-(CH,),-CO— o~ 0-CO-(CH,),-R
: 0400371947 ® . ® SF am — 3
CF
NS
= CFs pe CF,
CF, i , which as fluorine-containing radicals have the perfluerine-1H group or 1H-neopentyl group, are also used for fluorine-19-imaging.
U.S. Patent US 5,362,478 (VIVORX) indicates another structural type with expanded diagnostic use, in which the fluorocarbon/polymer shell combination is claimed for imaging purposes. Perfluorononane and human serum albumin are mentioned. This combination proves suitable, moreover, for using the fluorine atom as a probe for local temperature measurement and for determining the partial oxygen pressure. :
Perfluorocarbons are also claimed in U.S. Patent 4,586,511 for oxygen determination.
In German Patent DE 4008179 (Schering), fluorine-containing benzenesulfonamides are claimed as pH probes:
CF, : rN —NHSO,CH,CH,CO,H —/
For NMR diagnosis, compounds that contain iodine and fluorine atoms are also claimed as contrast-enhancing agents in WO 94/05335 and WO 94/22368 (both molecular biosystems):
] 8400 3/1947 ®o © -CHGH-COH
Et
I
NHCOCF, ! ~(Domcery C(CF,), } ~eseo CCF),
HN
The fluorine-paramagnetic metal ion combination is also claimed for fluorine-19- imaging, specifically for open-chain complexes in WO 94/22368 (Molecular Biosystems) with, e.g. a
N
HCc—hnoc” NT NY eo ~~ Neo. co, >
CCF), C(CFy), Gd CCF), CCF, and in EP 292 306 (TERUMO Kabushiki Kaisha) with, e.g.
. ®o © ;
N 7 0,67 wT ~~ Sn co, '0,C co,
FF
/
R= —CH,CF, . —an—{ Scie, ' a \
CF, F F { 9 CF, / —CH,CH—N CFs —on— BD
CF,
CF,
CF, but also for cyclic compounds, as they are mentioned in EP 628 316 (TERUMO Kabushiki
Kaisha) 0c” SN nC Noo; 0c” TN we co,
C ca ] ( ca )
N Ne _ ' N N ~~ ~~
AP CLE
Co, CO, a
CF; CF, CF,
Y/R Sha / “er ——CH:= CF . meee CH_CH—N * 2 \ _./ \ 3 = < \ CF,
CF, ~~
CF,
The combination of fluorine atom and rare-earth metal is also claimed for NMR- spectroscopic temperature measurements in DE 4317588 (Schering):
LN /S\ Co, _N N
Lat
OH
MN MN
Nr
CF, co,
Ln: Rare earths: La, Pr, Dy, Eu
While no interactions occur between the two nuclei in compounds that contain the elements fluorine and iodine, intensive interaction does occur in compounds that contain fluorine and paramagnetic centers (radicals, metal ions) and that are expressed in a shortening of the relaxation time of the fluorine nucleus. The extent of this effect depends on the number of unpaired electrons of the metal ion (Gd** > Mn" > Fe’ > Cu’) and on the removal between the paramagnetic ion and the F-atom.
The more unpaired electrons of the metal ion are present and the closer the latter are brought to the fluorine, the greater the shortening of the relaxation time of the fluorine nucleus.
The shortening of the relaxation time as a function of the distance from the paramagnetic ion becomes apparent in all nuclei with an uneven spin number, thus also in the case of protons, and gadolinium compounds are therefore widely used as contrast media in nuclear spin tomography (Magnevist™, Prohance™, Omniscan™, and Dotarem™).
In 'H-MR imaging ('"H-MRYD), however, relaxation time T' or T? of the protons, 1.€., mainly the protons of water, and not the reaction time of the fluorine nuclei, is measured and used for imaging. The quantitative measurement for the shortening of the relaxation time is relaxivity [L/mmol's]. Complexes of paramagnetic ions are successfully used for shortening relaxation times. In the following table, the relaxivity of several commercial preparations is indicated:
ol A Fo [/mmol's, 39°C, 0.47 T] [I/mmol's, 39°C, 0.47 T]
Only interactions between protons and the gadolinium ion are found in these compounds.
For these contrast media in water, a relaxivity of about 4 [1/mmol's] is thus observed.
Both fluorine compounds for fluorine-19-imaging, in which the shortened relaxation time of the fluorine nucleus is used, and non-fluorine-containing compounds, in which the relaxation time of protons of water is measured, are thus used successfully for MR imaging.
In the introduction of a perfluorocarbon-containing radical into a paramagnetic contrast medium, i.e., in the combination of properties that were previously known as suitable only for fluorine-imaging compounds, the relaxivity that relates to the protons of water also quickly increases, surprisingly enough, with compounds that were used for proton imaging. It now reaches values of 10-50 [1/mmol's] in comparison to values of between 3.5 and 3.8 [1/mmol's] as they were already cited for a few commercial products in the table above.
Perfluoroalkyl-containing metal complexes are already known from DE 196 03 033.1.
These compounds, however, cannot be used satisfactorily for all applications. Thus, there is still a need for contrast media for the visualization of malignant tumors, lymph nodes and necrotic tissue.
Malignant tumors metastasize in clusters in regional lymph nodes, whereby multiple lymph node stations may also be involved. Lymph node metastases thus are found in about 50- 69% of all patients with malignant tumors (Elke, Lymphographie (Lymphography), in:
Frommbhold, Stender, Thurn (eds.), Radiologische Diagnostik in Klinik und Praxis [Radiological
Diagnosis in Clinical Studies and in Practice], Volume IV, Thieme Verlag Stuttgart, 7th Ed.,
~~ 9£003/71947 ® i. A 1984). The diagnosis of a metastatic attack of lymph nodes is of great importance with respect to the treatment and prognosis of malignant types of diseases. With modern imaging methods (CT, US and MRI), lymphogenous evacuations of malignant tumors are detected only inadequately, since in most cases only the size of the lymph node can be used as a diagnostic criterion. Thus, small metastases in non-enlarged lymph nodes (< 2 cm) cannot be distinguished from lymph node hyperplasias without a malignant attack (Steinkamp et al., Sonographie und
Kermnspintomographie: Differentialdiagnostik von reaktiver Lymphknoten-vergréferung und
Lymphknoten-metastasen am Hals [Sonography and Nuclear Spin Tomography: Differential
Diagnosis of Reactive Lymph Node Enlargement and Lymph Node Metastasis on the Neck],
Radiol. Diagn. 33:158, 1992).
It would be desirable if a distinction could be made when using specific contrast media lymph nodes with metastatic attack and hyperplastic lymph nodes.
Direct x-ray lymphography (injection of an oily contrast medium suspension into a prepared lymph vessel) is known as an invasive method that is used only very rarely and that can visualize only small lymph drainage stations.
Fluorescence-labeled dextrans are also used experimentally in animal experiments to be able to observe lymphatic drainage after their interstitial administration. All commonly used markers for the visualization of lymph tracts and lymph nodes after interstitial/intracutaneous administration have in common the fact that they are substances with particulate character ("particulates," e.g., emulsions and nanocrystal suspensions) or large polymers (see above, WO 90/14846). Based on their inadequate local and systemic compatibility as well as their small lymphatic passageway, which causes inadequate diagnostic efficiency, the previously described preparations still do not prove optimally suitable for indirect lymphography, however.
Since the visualization of lymph nodes is of central importance for the early detection of metastatic attack in cancer patients, there is a great need for lymph-specific contrast medium preparations for diagnosis of corresponding changes of the lymphatic system.
The highest possible contrast medium concentration and high stability are just as
® J as the diagnostically relevant, most uniform possible lymphatic concentration over several lymph stations. The burden on the overall organism should be kept low by quick and complete excretion of the contrast medium. A quick start-up. if possible as early as within a few hours after the administration of contrast media, is important for the radiological practice. Good compatibility 1s necessary.
Largely for this reason, it is desirable to have available lymph-specific contrast media that in a diagnostic session allow both the primary tumor and a possible lymph node metastasizing to be visualized.
Another important area in medicine is the detection. localization and monitoring of necroses or infarctions. Thus, myocardial infarction is not a stationary process, but rather a dynamic process, which extends over a long period (weeks to months). The disease proceeds in about three phases, which are not strictly separated from one another, but rather are overlapping.
The first phase, the development of myocardial infarction, comprises the 24 hours after the infarction, in which the destruction from the subendocardium to the myocardium progresses like a shock wave (wave front phenomenon). The second phase, the already existing infarction, comprises the stabilization of the area in which fiber formation (fibrosis) takes place as a healing process. The third phase, the healed infarction, begins after all destroyed tissue is replaced by fibrous scar tissue. During this period, an extensive restructuring takes place.
Up until now, no precise and reliable process is known that enables the current phase of a myocardial infarction to be diagnosed in a living patient. To evaluate a myocardial infarction, it is of decisive importance to know how large the proportion of the tissue that is lost in the infarction is and at what point the loss took place, since the type of therapy depends on this knowledge.
Infarctions take place not only in the myocardium, but rather also in other tissues, especially in the brain.
While the infarction can be healed to a certain extent, in a necrosis, locally limited tissue death, only the harmful sequelae for the residual organism can be prevented or at least reduced.
® & can develop in many ways: by traumas, chemicals, oxygen deficiency or by radiation.
As in infarction, the knowledge of the extent and type of a necrosis is important for further medical treatment.
Tests to improve the localization of infarctions and necroses by using contrast media in non-invasive processes, such as scintigraphy or nuclear spin tomography, therefore already took place earlier. The literature is full of reports on attempts to use porphyrins for necrosis imaging.
The results that are achieved, however, paint a contradictory picture. Winkelman and Hoyes thus describe in Nature, 200, 903 (1967) that manganese-5,10,15,20-tetrakis(4-sulfonatophenyl)- porphyrin (TPPS) selectively accumulates in the necrotic portion of a tumor.
Lyon et al. (Magn. Res. Med. 4, 24 (1987)) observed, however, that manganese-TPPS is dispersed in the body, specifically in the kidney, liver, tumor and only in a small portion of the muscles. In this case, it is advantageous that the concentration in the tumor reaches its maximum only on the fourth day and only after the authors had increased the dose from 0.12 mmol/kg to 0.2 mmol/kg. The authors therefore also speak of a non-specific take-up of TPPS in the tumor. ~ Bockhurst et al. in turn report in Acta Neurochir 60, 347 (1994, Suppl.) that MnTPPS binds selectively to tumor cells.
Foster et al. (J. Nucl. Med. 26, 756 (1985)) in turn found that "11p-5,10,15,20-tetrakis-(4-
N-methyl-pyridinium)-porphyrin (TMPyP) does not accumulate in the necrotic portion, but rather in the living edge layers. It follows from the above that a porphyrin-tissue interaction exists and is obvious but not necessary.
In Circulation Vol. 90, No. 4, part 2, page 1468, Abstract No. 2512 (1994), Ni et al. report that they can visualize infarction areas with a manganese-tetraphenyl-porphyrin (Mn-TPP) and a gadolinium-mesoporphyrin (Gd-MP). In International Patent Application WO 95/31219, both substances were used in infarction and necrosis imaging. Authors Marchal and Ni write (see Example 3) that for the compound Gd-MP, the metal content of the infarction-kidney was high, similar to that of the non-infarcted organ, but that it was nine times as large for the myocardium in the case of infarcted tissue (Example 1). It was surprising that the ratio of the y 8200371947 ® , intensities in MRI for infarcted patients was comparatively high in comparison to healthy tissue in both cases with 2.10 or 2.19. Other metalloporphyrins have been described in
Application DE 19835082 (Schering AG).
Porphyrins tend to be stored in the skin, which results in a photosensitization. The sensitization can last for days, and even weeks. This in an undesirable side effect in using porphyrins as diagnostic agents. In addition, the therapeutic index for the porphyrins is only very small, since, e.g., for Mn-TPPS, an action is used only at a dose of 0.2 mmol/kg, but LDsp is already approximately 0.5 mmol/kg.
Contrast media for necrosis and infarction imaging that are not derived from the porphyrin skeleton are described in DE 19744003 (Schering AG), DE 19744004 (Schering AG) and WO 99/17809 (EPIX). To date, however, there are still no compounds that can be used satisfactorily as contrast media in infarction and necrosis Imaging.
The object of the invention was therefore to make available contrast media that can be used in particular for MRT-lymphography, but also for tumor diagnosis and necrosis and infarction imaging.
The object of the invention is achieved by the perfluoroalkyl-containing complexes with polar radicals of general formula I (K)1=G — {Z-Ry)u i {I) (R)p in which
Re is a perfluorinated, straight-chain or branched carbon chain with the formula -CuF2rE, in which E represents a terminal fluorine, chlorine, bromine, iodine or hydrogen atom, and n stands for numbers 4-3 0,
K stands for a metal complex of general formula II
13 £4003/1947 ® ([ COOR?
R'OOC —N n't Fey
NA ~~ ©
Noon (II) in which
R' means a hydrogen atom or a metal ion equivalent of atomic numbers 21-29, 31- 33, 37-39, 42-44, 49 or 57-83, provided that at least two R! stand for metal ion equivalents,
R’ and R?, independently of one another, represent hydrogen, C;-C5 alkyl, benzyl, phenyl, -CH20H or -CH20CH3, and
U represents -CsHs-O-CHa-w-, -(CH2)1.5-®, a phenylene group, -CH2-NHCO-CHaz-
CH(CH2COOH)-CsHa-w-, -CsHa-(OCH2CH2)o-1-, N(CH2COOH)-CHz-w or a Ci-
Ci2-alkylene group or a C7-Ci2-CsH4-O group that is optionally interrupted by one or more oxygen atoms, 1 to 3 -NHCO groups or 1- to 3 -CONH groups and/or is substituted with 1 to 3 -(CH2)o-sCOOH groups, whereby o stands for the binding site to -CO-, or of general formula III
COOR"
A N coo rR’ Po aoc NS =T
NP
\
COOR" {ZX%)
1 8200371947 in which R' has the above-mentioned meaning, R* represents hydrogen or a metal ion equivalent that is mentioned under R', and U' represents -C¢Hi-O-CHa-o-, whereby means the binding site to -CO- or of general formula IV
COOR?
NO
SOND NOR
\ A 3 a) 3 NY
ROOCT /
N wn ©
CCOR! (IV) in which R' and R? have the above-mentioned meaning or of general formulaV Aor VB
NCO
SN Coor \ —N
RWQOC™ /
NUN ~~CO0OR’ ~CCOR" (Vv a)
NT OR? 0 SN CooR' [Pn
A
NUNTEO0R! ~COOR" (Vv B) in which R' has the above-mentioned meaning,
or of general formula VI
WYO —_ Sl —— @) 0 w—e AA]
ROVE 7 yy
RWQOC— ~—CQOR" (VI) in which R' has the above-mentioned meaning, or of general formula VII
ROO —_ Q
Noa
R'QOC U +
R'COC NY
R'OOC—" {VIT) in which R' has the above-mentioned meaning, and
U' represents -CsHa-O-CHz-00-, whereby @ means the binding site to -CO-, and in radical K, optionally present free acid groups optionally can be present as salts of organic and/or inorganic bases or amino acids or amino acid amides,
G represents a radical that is functionalized in at least three places and that is selected from radicals a) to g) below (2)
H
& N(CH) =~ CO ¥
NH i
P
(b}
HH
Y #~CO-C —(CH,) aN we ad
® ® (c) = pup \
B w— VA ¥ nl
Ms : {d) i ~nT
CMY
We—nN M——
Mp
B
{e) y 3
Ls e
INFN pu—oN Nm
® © (£)
IN ~ JP = spe —(CH, )-C—N—CO-C—(CH, } 7 N ——w8
H LH 4H [ NH
R
{g)
TN TN
" | " 3 E: 2 ed Y B {n} 7 OOCN zs prCO : 0] 3 CO-(CHy)yrqr PH-CO a . NH
NH } 1 o (h) so that G represents radical (c) or (d) and R represents a complex that is selected from general formulas II and V, R must not be identical to radical K of the general formula, if Z stands for §-C(O)CH20 (CHa)z-¢, whereby a means the binding site of G to complex K, B is the binding site of G to radical R and y represents the binding site of G to radical Z,
Z stands for
STN
¥—NZ N—S05-¢ v-C(O)CH20(CHa)2-£, whereby v represents the binding site of Z to radical G, and & means the binding site of Z to perfluorinated radical Rs,
y 2003/1947 ® ® R represents a polar radical selected from complexes K of general formulas II to VII, whereby R' here means a hydrogen atom or a metal ion equivalent of atomic numbers 20-29, 31-33, 37-39. 42-44, 49 or 57-85, and radicals R?, rR’, R*, U and U' have the above-indicated meaning, whereby for the case that G represents radical (c) or (d) and R represents a complex that is selected from general formulas II and V, R must not be identical to radical K of general formula I, if Z stands for §-C(O)CH20(CHa)z-¢, or the folic acid radical or
R means a carbon chain with 2-30 C atoms that is bonded via -CO- or SO2-ora direct bond to radical G, in a straight line or branched, saturated or unsaturated, optionally interrupted by 1-10 oxygen atoms, 1-5 -NHCO groups, 1-5 -CONH groups, 1-2 sulfur atoms, 1-5 -NH groups or 1-2 phenylene groups, which optionally can be substituted with 1-2 OH groups, 1-2 NH2 groups, 1-2 -COOH groups, or 1-2 -SOsH groups, or optionally substituted with 1-8 OH groups, 1-3 -COOH groups, 1-2 SO3H groups, 1-5 NH: groups, 1-5 C1-C4 alkoxy groups, and 1, m, p, independently of one another, mean the whole numbers 1 or 2.
If the compound according to the invention is intended for use in NMR diagnosis, the metal ion of the signal-transmitting group must be paramagnetic. These are especially the, divalent and trivalent ions of the elements of atomic numbers 21-29, 42, 44 and 58-70. Suitable ions are, for example, the chromium(III) ion, iron(II) ion, cobalt(II) ion, nickel(Il) ion, copper(II) ion, praseodymium(IIl) ion, neodymium(III) ion, samarium(III) ion and ytterbium(III) ion.
Because of their strong magnetic moment, gadolinium(IIl), terbium(III), dysprosium(III), holmium(III), erbium(III), iron(II) and manganese(Il) ions are especially preferred.
ae 9200371947 ® ® For the use of the compounds according to the invention in nuclear medicine (radiodiagnosis and radiotherapy), the metal ion must be radioactive. For example, radioisotopes of the elements with atomic numbers 27, 29, 31-33, 37-39, 43, 49, 62. 64,70, 75 and 77 are suitable. Technetium, gallium, indium, rhenium. and yttrium are preferred.
If the compound according to the invention is intended for use in x-ray diagnosis, the metal ion is preferably derived from an element of a higher atomic number to achieve a sufficient absorption of x-rays. It was found that diagnostic agents that contain a physiologically compatible complex salt with metal ions of elements of atomic numbers 25, 26 and 39 as well as 57-83 are suitable for this purpose.
Manganese(1I), iron(II), iron(III), praseodymium(Ill), neodymium(IIl), samarium(lII), gadolinium(IIT), ytterbium(III) or bismuth(IIl) ions, especially dysprosium(III) ions and yttrium(III) ions, are preferred.
Acidic hydrogen atoms that are optionally present in R', i.e., those that have not been substituted by the central ion, can optionally be replaced completely or partially by cations of inorganic and/or organic bases or amino acids or amino acid amides.
Suitable inorganic cations are, for example, the lithium ion, the potassium ion, the calcium ion and especially the sodium ion. Suitable cations of organic bases are, i.a., those of primary, secondary or tertiary amines, such as, for example, ethanolamine, diethanolamine, morpholine, glucamine. N,N-dimethylglucamine and especially N-methylglucamine. Suitable cations of amino acids are, for example, those of lysine, arginine, and ornithine as well as the amides of otherwise acidic or neutral amino acids.
Especially preferred compounds of general formula [ are those with macrocyclic compound K of general formulas II, III, VB or VIL
Radical U in metal complex K preferably means -CHz- or CeHa-O-CHz-w, whereby » stands for the binding site to -CO-.
Alkyl groups R” and R’ in the macrocyclic compound of general formula II can be straight-chain or branched. By way of example, methyl, ethyl, propyl, isopropyl, n-butyl. 1-
) methyl-propyl. 2-methvipropyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, and 1.2- dimethylpropyl can be mentioned. Rand R’, independently of one another, preferably mean hydrogen or C;-Cy-alkyl.
In a quite especially preferred embodiment, R” stands for methyl and R’ stands for hydrogen.
The benzyl group or the phenyl group R*orR’ in macrocyclic compound K of general formula II can also be substituted in the ring.
Polar radical R in general formula I means complex K in a preferred embodiment, whereby the latter can also be a Ca* complex preferably in addition to a Gd>* complex or an
Mn" complex. Complexes K of general formulas II, III, VA or VII are especially preferred as polar radicals R. The latter as R' quite especially preferably exhibit a metal ion equivalent of atomic numbers 20, 25 or 64.
In another preferred embodiment, polar radical R has the following meanings: ~C (0) Cilia ClHaS0sH -C {0} CH,CCH; CH; OCH, CH,CH ~-C {Q) CH;OCH;CH:OH -C {0} CH,;0CH CH (OH) CH,CH -C{0)CH,;NH-C {O) CH;COOH -C{0Q)CH:CH (OH) CH,OH : -C (0) CH;0CH COOH -S0Q;CH;CH.COQH -C{0) -CgH;~ (m~COOH) = -C{0)CH-Q (CH) 2~CeH3~ (m~- COOH) 2 -C (0) CE0-CeEs—m—50si -C {O)CH-NBC (0) CH;NEC (0) CH2CCH.COOH . ~C{0)C¥;0CH,CH0CECOOR ~-C{0)CH,;0CH,CH (0H) CH,0-CH;CH,0OH -C (0) CE 0CH,CH (OH) CE.O0CH,~-CH { OH) -CH,CH
21 8200371947 o C -C (0) CHSC; H ~C{Q) CH.CH,OOCH ~C{OICH (CH) CH (CH; CH 0H ~C{QI CHO [ {CHR 20] 15TH: ~C{O) CHO [ {CE 20) 13-H -C{Q) CHOC {CHO 2 ~C{0) CH-CCH {CH OCH;CO0K 1 2 ~C {0} =CgH3- [m=-OCH-CODE) 5 ~CO~CHO- {CE 1 2C {CHa 20- (CE; 2:0 {CHy) 20TH, preferably -C(0O)CH:20{(CH2)20]4-CH3.
In another preferred embodiment, polar radical R means the folic acid radical.
Of the compounds of general formula I according to the invention, in addition those are preferred in which Rf means -CnF2q+1. n preferably stands for the numbers 4-15. Quite especially preferred are radicals -Cy4Fg, -CsF 13, -CsF 17, Ci2F25 and -C4F29 as well as the radicals of the compounds that are mentioned in the examples.
Radical G that is functionalized in at least three places in general formula I, which represents the "skeleton," means lysine radical (a) or (b) in a preferred embodiment of the invention.
Z means the linker that is indicated in general formula I, whereby the radical . ~ ¥—N: - N—~S0-¢€ is preferred.
The perfluoroalkyl-containing metal complexes with polar radicals of general formula I (X)1-G — (Z-Bg): (1 0 KR ; es in which K, G, R, Z, R¢, |, m and p have the above-indicated meaning, are produced, in a way that is known in the art, by a carboxylic acid of general formula Ila
22 ) 8200371947 ®o © oor
ANN RE RSG
NN - Ne Le CH roCCT A ”
Noo ' > 4 © aalel=y (ria) in which R® means a metal ion equivalent of atomic numbers 21-29, 31-33, 37-39, 42-44, 49 or 57-83 or a carboxy! protective group, and R*, R® and U have the above-mentioned meaning, or a carboxylic acid of general formula Illa oR
NN COOK 0 \ 71 ¥ ] a 5 MN N u-——" "0H
RTOCC / \
NA
COOR? {ZIIa) in which RY, R’, and U' have the above-mentioned meaning or a carboxylic acid of general formula [Va
COOR® ’ AN g on
H
R’coc” / \
NN ©
COOR® {Iva}
. ’ 23 8400371947 ® : in e. Rand R” have the above-mentioned meaning or a carboxylic acid of general formula Va or Vb ~ COOH 5
ANTS OH An COOR_ ( CooR? ~~ N_Coor®
N \
RP00C™ 4 5 Hooc™
No NT COOR, \ ,—COOR® vw ~—COCR” NL coor® (Va) (Vb) in which R” has the above-mentioned meaning or a carboxylic acid of general formula Via
R°00C — —CO-OH
R*00C—~ ~~—COOR’ (VIz) in which R® has the above-mentioned meaning or a carboxylic acid of general formula VIIa
R°00C — | i
R*00C—" NU" ~CH
RO0C—
R°00C—" . (Vila) in which R® and U' have the above-mentioned meanings, being reacted in optionally activated form with an amine of general formula VIII
HB -G — (Z~Re)m (VIII) (R)p in which G, R, Z, Rt, m and p have the indicated meaning, in a coupling reaction and optionally
2 8200371947 ® | i _- cleavage of optionally present protective groups to form a metal complex of general formula I, or if R® has the meaning of a protective group, being reacted after cleavage of these protective groups in a subsequent step in a way that is known in the art with at least one metal oxide or metal salt of an element of atomic numbers 21-29, 31-33, 37-39, 42-44, 49 or 57-83, and then, if desired, optionally present, acidic hydrogen atoms being substituted by cations of inorganic and/or organic bases, amino acids or amino acid amides.
The carboxylic acids of general formulas IIa to VIIA that are used are either known compounds or are produced according to the process described in the examples. Thus, the production of carboxylic acids of general formula IIa is known from DE 196 52 386. The production of carboxylic acids of general formula Illa can be carried out analogously to Example 4 of this application. The production of the carboxylic acids of general formula IVa can be derived from DE 197 28 954.
A precursor for compounds of general formula VA is N’-(2,6-dioxomorpholinoethyl)-N°- : (ethoxycarbonylmethyl)-3,6-diaza-octanedioic acid, which is described in EP 263 059.
The compounds of general formula VB are derived from the isomeric diethylenetriamine- pentaacetic acid, which binds via the acetic acid that is on the center N atom. This DTPA is ~ described in Patents DE 195 07 819 and DE 195 08 058.
Compounds of general formula VI are derived from N-(carboxymethyl)-N-[2-(2,6-dioxo- 4-morpholinyl)-ethyl]-glycine, whose production is described in J. Am. Oil. Chem. Soc. (1982), 59 (2), 104-107. :
Compounds of general formula VII are derived from 1-(4-carboxymethoxybenzyl)- ethylenediamine tetraacetic acid, whose production was described in Patent US 4.622.420.
The production of amines of general formula VIII is described in detail in the examples of this application and can be carried out analogously to the processes described in the examples.
It has been shown that the metal complexes according to the invention are especially
2s 8200371947 ® | i. for NMR diagnosis and x-ray diagnosis, but also for radiodiagnosis and radiotherapy.
The subject of the invention is therefore also the use of the perfluoroalkyl-containing metal complexes according to the invention with polar radicals for the production of contrast media for use in NMR diagnosis and x-ray diagnosis, especially for lymphography, for tumor diagnosis, and for infarction imaging and necrosis imaging, as well as in radiodiagnosis and radiotherapy.
The compounds according to the invention are extremely well suited for use in interstitial lymphography and especially in intravenous lymphography. In addition, they can also be used for visualization of the vascular space (blood-pool agents).
Subjects of the invention are also pharmaceutical agents that contain at least one physiologically compatible compound according to the invention, optionally with the additives : that are commonly used in galenicals.
The compounds of this invention are distinguished by a very good systemic compatibility and a high lymph node concentration in three successive lymph node stations (which is important especially for i.v. lymphography). They are thus especially well suited for use in MRT lymphography.
The compounds according to the invention are also extremely well suited for detecting and localizing vascular diseases, since they are dispersed exclusively in the latter in the administration in the intravascular space. The compounds according to the invention make it possible, with the help of nuclear spin tomography, to distinguish between tissue that is well supplied with blood and tissue that is poorly supplied with blood and thus to diagnose an ischemia. Because of its anemia, infarcted tissue can also be distinguished from surrounding healthy or ischemic tissue when the contrast media according to the invention are used. This is of special importance if the point is, e.g., to distinguish a myocardial infarction from an ischemia.
Compared to the macromolecular compounds previously used as blood-pool agents, such as, for example, Gd-DTPA-polylysine, the compounds according to the invention also show a higher T'-relaxivity and thus are distinguished by an increase of signal intensity in NMR imaging. Since in addition they have an extended retention in the blood space, they can also be
A
2c 8200371947 ® ) ines in relatively small doses (of, e.g., < 50 nmol of Gd/l of body weight). The compounds according to the invention are primarily quickly and as completely as possible eliminated from the body, however.
It was also shown that the compounds according to the invention accumulate in areas with elevated vascular permeability, such as, e.g.. in tumors; they make it possible to make statements on the perfusion of tissues, provide the possibility of determining the blood volumes in tissues, to selectively shorten the relaxation times or densities of the blood and to graphically visualize the permeability of blood vessels. Such physiological data cannot be obtained by the use of extracellular contrast media, such as, e.g., Gd-DTPA (Magnevist™). From these considerations also arise their uses in the modern imaging processes of nuclear spin tomography and computer tomography: specific diagnosis of malignant tumors, early therapy control in cytostatic, antiphlogistic or vasodilatative therapy, early detection of underperfused areas (e.g. in the myocardium); angiography in vascular diseases, and detection and diagnosis of sterile or infectious inflammations.
The production of the pharmaceutical agents according to the invention is carried out ina way that is known in the art by the complex compounds according to the invention -- optionally with the addition of the additives that are commonly used in galenicals -- being suspended or dissolved in aqueous medium and then the suspension or solution optionally being sterilized.
Suitable additives are, for example, physiologically harmless buffers (such as, for example, tromethamine), additives of complexing agents (such as, for example, diethylenetriamine- pentaacetic acid) or weak complexes or the Ca-complexes that correspond to the metal complexes according to the invention or -- if necessary -- electrolytes such as, for example, sodium chloride or -- if necessary -- antioxidants, such as, for example, ascorbic acid.
If suspensions or solutions of the agents according to the invention in water or physiological salt solution are desired for enteral or parenteral administration or other purposes, they are mixed with one or more adjuvant(s) that are commonly used in galenicals [for example, © methyl cellulose, lactose, mannitol] and/or surfactant(s) [for example, lecithins, Tween™,
7 3800371947 ® " and/or flavoring substance(s) for taste correction [for example, ethereal oils].
Basically, it is also possible to produce the pharmaceutical agents according to the invention without isolating the complexes. In any case, special care must be used to carry out the chelation so that the complexes according to the invention are practically free of non-complexed metal ions that have a toxic effect.
This can be ensured, for example, with the aid of color indicators, such as xylenol orange, by control titrations during the production process. The invention therefore also relates to a process for the production of the complex compounds and their salts. As a final precaution, there remains purification of the isolated complex.
In the in-vivo administration of the agents according to the invention, the latter can be administered together with a suitable vehicle, such as, for example, serum or physiological common salt solution and together with another protein, such as, for example, human serum albumin (HSA).
The agents according to the invention are usually administered parenterally, preferably i.v. They can also be administered intravascularly or interstitially/intracutaneously depending on whether bodily vessels or tissue are to be studied.
The pharmaceutical agents according to the invention preferably contain 0.1 pmol - 2 mol/l of the complex and are generally dosed in amounts of 0.0001 - 5 mmol/kg.
The agents according to the invention meet the many requirements for suitability as contrast media for nuclear spin tomography. After oral or parenteral administration, they are thus extremely well suited for enhancing the informational value of the image that is obtained with the aid of a nuclear spin tomograph by increasing the signal intensity. They also show the high effectiveness that is necessary to load the body with the smallest possible amount of foreign substances and the good compatibility that is necessary to maintain the non-invasive character of the studies.
The good water solubility and low osmolality of the agents according to the invention make it possible to produce highly concentrated solutions, so as to keep the volume burden of the .
. 0200371947 ® : ir ory system within reasonable limits and to offset the dilution by bodily fluids. In addition, the agents according to the invention show not only a high stability in vitro, but also a surprisingly high stability in vivo, so that a release or an exchange of the ions -- which are inherently toxic -- and which are bonded to the complexes can take place only extremely slowly within the time in which the new contrast media are completely excreted again.
In general, the agents according to the invention for use as NMR diagnostic agents are dosed in amounts of 0.001-5 mmol/kg, preferably 0.005-0.5 mmol/kg.
The complex compounds according to the invention also can advantageously be used as susceptibility reagents and as shift reagents for in-vivo-NMR spectroscopy.
Based on their advantageous radioactive properties, and the good stability of the complex compounds contained therein, the agents according to the invention are also suitable as radiodiagnostic agents. Details of such a use and dosage are described in, e.g., "Radiotracers for
Medical Applications," CRC Press, Boca Raton, Florida.
The compounds and agents according to the invention can also be used in positron- emission tomography, which uses positron-emitting isotopes, such as, e.g., “se, “sc, Fe, Co,
Ga and ¥Y (Heiss, W. D.; Phelps, M. E.; Positron Emission Tomography of Brain, Springer
Verlag Berlin, Heidelberg, New York 1983).
The compounds according to the invention are also suitable, surprisingly enough, for differentiating malignant and benign tumors in areas without blood-brain barriers.
They are also distinguished in that they are completely eliminated from the body and thus are well-tolerated.
Since the substances according to the invention accumulate in malignant tumors (no diffusion in healthy tissue, but high permeability of tumor vessels), they can also support the radiation therapy of malignant tumors. The latter is distinguished from the corresponding diagnosis only by the amount and type of the isotope used. The purpose in this case is the destruction of tumor cells with high-energy shortwave radiation with as small a range of action as possible. For this purpose, interactions of the metals (such as. e.g., iron or gadolinium) that are
29 0400371947 ® cone in the complexes are used with ionizing radiation (e.g., X-rays) or with neutron rays.
By this effect, the local radiation dose at the site where the metal complex is located (e.g. in tumors) is significantly increased. To produce the same radiation dose in malignant tissue, the radiation exposure for healthy tissue can be considerably reduced when using such metal complexes and thus side effects imposing a burden for the patients are avoided. The metal- complex-conjugates according to the invention are therefore also suitable as radiosensitizing substances in radiation therapy of malignant tumors (e.g., use of Mossbauer effects or in neutron capture therapy). Suitable B-emitting ions are, for example, 3c, Ysc, “3c, Ga, Ga and *°Y.
Suitably short half-lives that have a-emitting ions are, for example, gi, 22g; Bi and 24g; whereby Bis preferred. A suitable photon- and electron-emitting ion is 18d, which can be obtained from "Gd by neutron capture.
If the agent according to the invention is intended for use in the variant of radiation therapy proposed by R. L. Mills et al. (Nature Vol. 336, (1988), p. 787), the central ion must be derived from a Mossbauer isotope, such as, for example, Fe or °'Eu.
In the in-vivo administration of the agents according to the invention, the latter can be administered together with a suitable vehicle, such as, for example, serum, or physiological common salt solution and together with another protein, such as, for example, human serum albumin. In this case, the dosage depends on the type of cellular disorder, the metal ion that is used and the type of imaging method.
The agents according to the invention are usually administered parenterally, preferably i.v. They can also -- as already discussed -- be administered intravascularly or interstitially/intracutaneously depending on whether bodily vessels or tissue are to be studied.
The agents according to the invention are extremely well suited as x-ray contrast media, whereby it is especially to be emphasized that no displays of the anaphylaxis-like reactions known from the iodine-containing contrast media can be detected in biochemical- pharmacological studies with them. Because of the advantageous absorption properties in the areas of higher tube voltages, they are especially valuable for digital subtraction techniques.
® ’ 0 general, the agents according to the invention for use as X-ray contrast media analogously to the meglumine-diatrizoate example are dosed in amounts of 0.1-5 mmol/kg, preferably 0.25-1 mmol/kg. ]
In particular, higher blood concentrations are achieved with the compounds according to the invention than with extracellular contrast media. They are dispersed after i.v. administration only into the intravascular space and thus have a decisive advantage compared to the extracellular contrast media.
a 0200371947 oo Oo
Example 1a 2-N-Trifluoroacetyl-6-N-benzyloxycarbonyl-lysine : 100 g (356.7 mmol) of 6-N-benzyloxycarbonyl-lysine is dissolved in a mixture that consists of 1000 ml of trifluoroacetic acid ethyl ester/500 ml of ethanol, and it is stirred for 24 hours at room temperature. It is evaporated to the dry state, and the residue is crystallized from diisopropyl ether.
Yield: 128.9 g (96% of theory) of a colorless, crystalline powder.
Elementary analysis:
Cld: C51.07 H5.09 F 15.14 N 7.44
Fnd: C51.25 HS5.18 F 15.03 N 7.58 :
Example 1b 2-N-Trifluoroacetyl-6-N-benzyloxycarbonyl-lysine-{ 1 -(4-perfluorooctylsulfonyl)piperazine]- amide 164.2 g (0.664 mmol) of EEDQ (2-ethoxy-1 ,2-dihydroquinoline- 1-carboxylic acid ethyl ester) is added at 0°C to 125 g (332 mmol) of the title compound of Example 1a and 188.7 g (332 mmol) of 1-perfluorooctylsulfonyl-piperazine (produced according to DE 19603033) in 800 ml : of tetrahydrofuran, and it is stirred overnight at room temperature. It is evaporated to the dry state in a vacuum and chromatographed on silica gel (mobile solvent: dichloromethane/ methanol=20:1).
Yield: 286 g (93% of theory) of a colorless solid.
Elementary analysis:
Cld: C36.30 H2.85 F41.01 N6.05 S3.46
Fnd: C 36.18 H2.94 F 40.87 N 5.98 $3.40 oe 0 6-N-Benzyloxycarbonyl-lysine-[ 1-(4-perfluorooctvisulfonyl)-piperazine]-amide
Ammonia gas is introduced at 0°C for one hour into a solution that consists of 280 g (302.2 mmol) of the title compound of Example 1b in 2000 ml of ethanol. It is then stirred for four hours at 0°C. It is evaporated to the dry state. and the residue is absorptively precipitated from water. The solid is filtered off and dried in a vacuum (50°C).
Yield: 243.5 g (97% of theory) of an amorphous solid.
Elementary analysis:
Cld: C37.60 H3.28 F38.89 N6.75 S3.86
Fnd: C37.15 H 3.33 F38.78 N6.68 S 3.81
Example 1d 6-N-Benzyloxycarbonyl-2-N-(3,6,9,12,15-pentaoxahexadecanoyl)-lysine[ 1-(4- perfluorooctylsulfonyl)-piperazine]-amide
A solution that consists of 19.93 g (70 mmol) of 3,6,9,12,15-pentaoxahexadecanoic acid chloride in 50 ml of dichloromethane is added in drops at 0°C to 50 g (60.20 mmol) of the title compound of Example 1c and 7.10 g (70 mmol) of triethylamine, dissolved in 350 ml of dichloromethane, and it is stirred for three hours at 0°C. 200 ml of 5% aqueous hydrochloric acid is added, and it is stirred for 5 minutes at room temperature. The organic phase is separated, dried on magnesium sulfate and evaporated to the dry state in a vacuum. The residue is chromatographed on silica gel (mobile solvent: dichloromethane/acetone = 15:1).
Yield: 53.7 g (93% of theory) of a colorless, viscous oil.
Elementary analysis:
Cld: C33.83 H4.94 F334 N 5.84 S 33.69
Fnd: C3375 H5.05 F329 N5.78 $33.75
33 8200371947 eo 0 2-N-(3,6.9,12,15-Pentaoxahexadecanoyl)-lysine{ 1 -(4-perfluorooctylsulfonyl)-piperazine]-amide 50 g (52.15 mmol) of the title compound of Example 1d is dissolved in 500 ml of ethanol, and 6 g of palladium catalyst (10% Pd/C) is added. It is hydrogenated at room temperature. Catalyst is filtered out, and the filtrate is evaporated to the dry state in a vacuum.
Yield: 43.0 g (quantitative) of a colorless solid.
Elementary analysis: :
Cld: C 27.68 H5.01 F39.17 N6.79 $3.89
Fnd: C 27.60 H5.13 F 39.09 N 6.68 S 3.81
Example 1f 6-N-[1,4,7-Tris(carboxylatomethyl)-1,4,7,1 0-tetraazacyclododecane- 10-(pentanoyl-3-aza-4-oxo-
S-methyl-5-y1)-2-N-(3,6,9,12,15-pentaoxahexadecanoyl)-lysine( 1 -(4-perfluorooctylsulfonyl)- piperazine]-amide, Gd complex g (24.25 mmol) of the title compound of Example le, 2.79 g (24.25 mmol) of N- hydroxysuccinimide, 2.12 g (50 mmol) of lithium chloride and 15.27 g (24.25 mmol) of 1,4,7- tris(carboxylatomethyl)-10-[(3-aza-4-0x0-5 -methyl-5-yl)]-pentanoic acid]-1,4,7,10- tetraazacyclododecane, Gd complex are dissolved in 200 ml of dimethyl sulfoxide while being heated slightly. At 10°C, 8.25 g (40 : mmol) of N,N-dicyclohexylcarbodiimide is added, and it is then stirred overnight at room temperature. The solution is poured into 3000 ml of acetone and stirred for 10 minutes. The precipitated solid is filtered off and then purified by chromatography (silica gel RP-18, mobile solvent: gradient that consists of water/ethanol/acetonitrile).
Yield: 28.21 g (81% of theory) of a colorless solid.
Water content: 11.0%
34 ~ 8800371947 ® ® Elementary analysis (relative to anhydrous substance):
Cld: C31.78 H4.84 F22.49 N 878 S223 Gd 10.95
Fnd: C31.74 H4.98 F 22.39 N 8.69 S$2.15 Gd 10.87
Example 22 6-N-[3,9-Bis(t-butyloxycarbonylmethyl)-3,6,9-triazaundecane- 1,1 1-dicarboxylic acid bis(t- butylester)-6-carbonylmethyl]-2-N-[3,6,9,12,15-pentaoxahexadecanoyl)-lysine-[1-(4- perfluorooctylsulfonyl)-piperazine]-amide 8.25 g (40 mmol) of N.N-dicyclohexylcarbodiimide is added at 0°C to a solution that consists of 20 g (24.08 mmol) of the title compound of Example le, 14.88 g (24.08 mmol) of 3,9-bis(t-butyloxycarbonylmethyl-3,6,9-triazaundecane- 1,1 1 -dicarboxylic acid-bis(t-butylester) and 2.77 g (24.08 mmol) of N-hydroxysuccinimide, dissolved in 150 ml of dimethylformamide.
It is stirred for 3 hours at 0°C, then overnight at room temperature. Precipitated urea is filtered out, the filtrate is evaporated to the dry state in a vacuum and chromatographed on silica gel (mobile solvent = dichloromethane/ethanol = 20:1).
Yield: 31.61 g (91% of theory) of a viscous oil.
Elementary analysis:
Cld: C40.80 H6.71 F 22.39 N6.80 $2.22
Fnd: C40.72 H6.82 F 2230 N6.75 S2.14 6-N-[6-Carbonylmethyl-3,9-bis(carboxylatomethyl)-3,6,9-triazaundecanedicarboxylic acid-1- carboxy-11-carboxylato-]-2-N-(3,6,9,12,1 5-penatoxahexadecanoyl)-lysine-[ 1-(4- perfluorooctylsulfonyl)-piperazine]-amide, Gd complex, sodium salt g (20.8 mmol) of the title compound of Example 2a is dissolved in 300 ml of trifluoroacetic acid and stirred for 5 hours at room temperature. It is evaporated to the dry state,
E ~~ ®2003/1947 ® the @. is taken up in 300 ml of water and set at pH 2.5 with 10% aqueous NaOH. Then 3.77 g (10.4 mmol) of gadolinium oxide is added, and it is stirred for 3 hours at 60°C. It is allowed to reach room temperature and set at pH 7.4 with sodium hydroxide solution. Itis evaporated to the dry state, and the residue is purified on silica gel RP-18. (Mobile solvent: gradient that consists of water/acetonitrile).
Yield: 19.18 g (67% of theory) of a colorless, amorphous solid.
Water content: 9.8%
Elementary analysis (relative to anhydrous substance):
Cld: C 28.80 H4.25F23.47N 7.125233 Gd 11.48 Na 1.67
Fnd: C 28.67 H4.34F 23.38 N 7.0382.27Gd 11.37 Na 1.74
Example 3a
Lysine-[ 1-(4-perfluorooctylsulfonyl-piperazine}-amide 20 g (24.08 mmol) of the title compound of Example lc is dissolved in 300 ml of ethanol, and 4 g of palladium catalyst (10% Pd/C) is added. It is hydrogenated at room temperature.
Catalyst is filtered out, and the filtrate is evaporated to the dry state in a vacuum.
Yield: 16.77 g (quantitative) of a colorless solid.
Elementary analysis:
Cld: C31.04 H3.04 F46.38 N 8.04 S4.60
Fnd: C 30.97 H3.15 F46.31 N 7.98 S4.51
Example 3b 2,6-N,N'-Bis[1,4,7-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecane-1 0-(pentanoyl-3-aza- 4-ox0-5-methyl-3-y1)]-lysine-[ 1-(4-perfluorooctylsulfonyl-piperazine]-amide, Gd complex g (14.36 mmol) of the title compound of Example 3a, 3.34 g (29 mmol) of N-
® a. S— 2.54 g (mmol) of lithium chloride and 18.26 g (29 mmol) of 1,4,7- tris(carboxylatomethyl)-1 0-(3-aza-4-oxo-5-methyl-5yl) 1.4,7,1 0-tetraazacyclododecane-Gd complex are dissolved in 200 ml of dimethyl sulfoxide while being heated slightly. At 10°C, 12.38 g (60 mmol) of N,N-dicyclohexylcarbodiimide is added, and it is then stirred overnight at room temperature. The solution is poured into 3000 ml of acetone and stirred for 10 minutes.
The precipitated solid is filtered off and then purified by chromatography (silica gel RP-18, mobile solvent: gradient that consists of water/ethanol/acetonitrile). Yield: 19.02 g (69% of ° theory) of a colorless solid.
Water content: 11.3%
Elementary analysis (relative to anhydrous substance):
Cld: C 35.03 H4.04 F 16.82 N 10.21 S1.67 Gd 16.38
Fnd: C 34.96 H4.13 F 16.74 N 10.16 S1.61 Gd 16.33
Example 4a 2-[4-(3-Oxapropionic acid ethyl ester)]-phenylacetic acid methyl ester 233.8 g (1.4 mol) of 2-bromoacetic acid ethyl ester is added to 200 g (1.204 mol) of 4- hydroxyphenylacetic acid methyl ester and 212 g (2 mol) of sodium carbonate in 2000 ml of acetone, and it is refluxed for 5 hours. The solid is filtered off and evaporated to the dry state in a vacuurh. The residue is chromatographed on silica gel (mobile solvent: n-hexane/ethyl acetate = 15:1).
Yield: 288.5 g (95% of theory) of a colorless oil.
Elementary analysis:
Cld: C 61.90 H6.39
Fnd: C 61.75 H6.51
®2003/1947 ®e Oo 2-[4-(3-Oxapropionic acid ethyl ester)]-phenyl-2-bromoacetic acid methyl ester 201 g (1.13 mol) of N-bromosuccinimide and 100 mg of dibenzyl peroxide are added to 285 g (1.13 mol) of the title compound of Example 4a, dissolved in 2000 ml of carbon : tetrachloride, and it is refluxed for 8 hours. It is cooled in an ice bath, the precipitated succinimide is filtered off, and the filtrate is evaporated to the dry state in 2 vacuum. The residue is purified on silica gel (mobile solvent: n-hexane/acetone = 15:1).
Yield: 359.2 g (96% of theory) of a colorless, viscous oil. :
Elementary analysis:
Cld: C 47.28 H4.57 Br24.16
Fnd: C 47.19 H4.71 Br24.05
Example 4¢ 2-[4-(3-Oxapropionic acid ethyl ester)]-phenyl-2-[1-(1 .4,7,10-tetraazacyclododecan-7-yl]-acetic acid methyl ester 350 g (1.057 mol) of the title compound of Example 4b is added to 603 g (3.5 mol) of 1,4,7,10-tetraazacyclododecane in 6000 ml of chloroform, and it is stirred overnight at room temperature. It is extracted 3 times with 3000 ml of water, the organic phase is dried on magnesium sulfate and evaporated to the dry state in a vacuum. The residue is used in the next reaction (3d) without further purification.
Yield: 448 g (quantitative) of a viscous oil. i
Elementary analysis:
Cld: C59.70 H8.11 N 13.26
Fnd: C 59.58 H 8.20 N 13.18
3 8200371947 ® 90. 2-[4-(3-Oxapropionic acid)]-phenyl-2-[1,4,7-tris(carboxymethyl)-1,4.7,10-tetraaza- cyclododecan-10-yl]-acetic acid 445 g (1.053 mol) of the title compound of Example 4c and 496 g (5.27 mol) of chloroacetic acid are dissolved in 4000 ml of water. The pH is set at 10 with 30% aqueous sodium hydroxide solution. Itis heated to 70°C, and the pH is kept at 10 by adding 30% aqueous sodium hydroxide solution. Itis stirred for 8 hours at 70°C. The pH is then set at 13 and refluxed for 30 minutes. The solution is cooled in an ice bath and set at a pH of 1 by adding concentrated hydrochloric acid. It is evaporated to the dry state in a vacuum. The residue is taken up in 4000 ml of methanol and absorptively precipitated for one hour at room temperature.
Precipitated common salt is filtered out, the filtrate is evaporated to the dry state, and the residue is purified on silica gel RP-18 (mobile solvent: gradient that consists of water/ethanol/ acetonitrile).
Yield: 403 g (69% of theory) of a colorless solid. :
Water content: 10.2%
Elementary analysis (relative to anhydrous substance):
Cld: C5198 H6.18 N 10.10 © Fnd: C51.80 H631 N 10.01
Example de 2-[4-(3-Oxapropionic acid)]-phenyl-2-[1,4,7-tris(carboxymethyl)-1,4,7,10-tetraaza- cyclododecan-10-yl]-acetic acid, Gd complex 130.73 g (360.65 mmol) of gadolinium oxide is added to 400 g (721.3 mmol) of the title compound of Example 4d in 2000 ml of water, and it is stirred for 5 hours at 80°C. The solution is filtered, and the filtrate is freeze-dried.
Yield: 511 g (quantitative) of an amorphous solid.
23 ~ 8200371947 ® ’ 9... content: 11.0%
Elementary analysis (relative to anhydrous substance):
Cld: C40.67 H4.41 Gd22.19 N 7.98
Fnd: C40.51 H4.52 Gd22.05 N 8.03
Example 4f 2,6-N,N'-Bis{2-[4-(3-oxapropionyl)-phenyl]-2-[1 ,4,7-tris(carboxylatomethyl)-1,4,7,10- tetraazacyclododecan-10-yl]-acetic acid]-lysine- [4-perfluorooctylsulfonyl)-piperazine}-amide, digadolinium complex, disodium salt g (14.36 mmol) of the title compound of Example 3a, 3.45 g (30 mmol) of N- hydroxysuccinimide, 2.54 g (60 mmol) of lithium chloride and 21.26 g (30 mmol) of the title compound of Example 4e are dissolved in 250 ml of dimethyl sulfoxide while being heated slightly. At 10°C, 16.51 g (80 mmol) of N,N-dicyclohexylcarbodiimide is added, and it is then stirred overnight at room temperature. The solution is poured into 2000 ml of acetone and stirred for 10 minutes. The precipitated solid is filtered off and then purified by chromatography (silica gel RP-18, mobile solvent: gradient that consists of water/ethanol/acetonitrile). It is dissolved in a little water, set at pH 7.4 with sodium hydroxide solution and freeze-dried.
Yield: 21.02 g (69% of theory) of a colorless solid.
Water content: 11.2%
Elementary analysis (relative to anhydrous substance):
Cld: C3736 H3.66F 1522 Gd 14.82 N 7.92Na2.17S 1.51
Fnd: C3728 H3.74F 15.14 Gd 14.75 N 8.03 Na 2.23 S 1.46
40 8200371947 © 0. 2,6-N.N'-Bis[6-carbonylmethyl-3,9-bis(t-butyloxycarbonylmethyl)-3 .6,9-triazaundecane-1,11- dicarboxylic acid-bis(t-butylester)]-lysine-[1 -(4-perfluorooctylsulfonyl)-piperazine]-amide 10.32 g (50 mmol) of N,N-dicyclohexylcarbodiimide is added at 0°C to a solution that consists of 10 g (14.36 mmol) of the title compound of Example 3a, 18.53 g (30 mmol) of 3,9- bis(t-butyloxycarbonylmethyl)-6-carboxymethyl-3,6,9-triazaundecane- 1,11-dicarboxylic acid- bis(t-butylester) and 3.45 g (30 mol) of N-hexoxysuccinimide, dissolved in 150 ml of dimethylformamide. It is stirred for 3 hours at 0°C, then overnight at room temperature.
Precipitated urea is filtered out, the filtrate is evaporated to the dry state in a vacuum and chromatographed on silica gel (mobile solvent: dichloromethane/ethanol = 20:1).
Yield: 19.60 g (72% of theory) of a viscous oil.
Elementary analysis:
Cld: C49.41 H6.75 F 17.03 N 7.39 S1.69
Fnd: C49.35 H6.82 F 16.92 N7.32 S1.62
Example Sh 2,6-N,N-Bis[6-carbonylmethyl-3,9-bis(carboxylatomethyl)-3,6,9-triazaundecanedicarboxylic acid-1-carboxy-11-carboxylato-lysine-{1 -(4-perfluorooctylsulfonyl)-piperazine}-amide, Gd complex, sodium salt] g (7.91 mol) of the title compound of Example Sa is dissolved in 50 ml of chloroform, and 200 ml of trifluoroacetic acid is added. It is stirred for 10 minutes at room temperature. It is evaporated to the dry state in a vacuum, and the residue is dissolved in 150 ml of water. 2.87 g (7.91 mmol) of gadolinium oxide is added, and it is stirred for 5 hours at 80°C. It is allowed to cool to room temperature and set at pH 7.4 with 2N sodium hydroxide solution. The solution is evaporated to the dry state in a vacuum and purified on RP-18 (mobile solvent: gradient that consists of water/ethanol/acetonitrile).
a1 «4003/1 947 ® ® 8.11 g (57% of theory) of a colorless, amorphous solid.
Water content: 9.6%
Elementary analysis (relative to anhydrous substance):
Cld: C30.70 H3.08 Gd 17.48 N 7.78 Na 2.56 S 1.78
Fnd: C30.58 H3.19 Gd 17.42 N 7.71 Na2.68 S1.72
Example 6a 6-N-Benzyloxycarbonyl-2-N-[6-carboxylmethyl-3,9-bis(t-butyloxycarbonylmethyl)-3,6,9- triazaundecane-1,11-dicarboxylic acid-bis(t-butylester)]-lysine-[ 1(4-perfluorooctylsulfonyl)- piperazine ]-amide 8.25 g (40 mol) of N,N-dicyclohexylcarbodiimide is added at 0°C to a solution that consists of 20 g (24.08 mmol) of the title compound of Example 1c, 14.88 g (24.08 mmol) of 3,9-[bis(t-butyloxycarbonylmethyl)-6-carboxymethyl-3,6,9-triazaundecane-1,1 1 -dicarboxylic ~ acid-bis(t-butylester) and 2.88 g (25 mol) of N-hydroxysuccinimide, dissolved in 100 ml of dimethylformamide. It is stirred for 3 hours at 0°C, then overnight at room temperature.
Precipitated urea is filtered out, the filtrate is evaporated to the dry state in a vacuum and chromatographed on silica gel (mobile solvent: dichloromethane/ethanol = 20:1).
Yield: 27.21 g (79% of theory) of a viscous oil.
Elementary analysis:
Cld: C47.03 H5.64 F22.58 N6.85 S2.24
Fnd: C 46.94 H5.58 F22.65 N6.84 S2.31
2 8200371947 2-N-[Carbonylmethyl-3,9-bis(t-butyloxycarbonylmethyl)-3 ,6,9-triazaundecane-1,11-dicarboxylic acid-bis(t-butylester)]-lysine-[ 1 -(4-perfluorooctylsulfonyl)-piperazine]-amide 25 g (17.48 mmol) of the title compound of Example 6a is dissolved in 350 ml of ethanol, and 5 g of palladium catalyst (10% Pd/C) is added. It is hydrogenated at room temperature.
Catalyst is filtered out, and the filtrate is evaporated to the dry state in a vacuum.
Yield: 22.66 g (quantitative) of a colorless solid.
Elementary analysis:
Cld: C44.48 H5.75 F 24.92 N7.56 S247
Fnd: C 44.59 HS5.81 F25.03 N7.46 S252
Example 6c 6-N-[1 .4,7-Tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecane-1 0-(pentanoyl-3-aza-4-oxo- 5-methyl-5yl)]-2-N-[6-carbonylmethyl-3,9-bis(t-butyloxycarbonylmethyl)-3,6,9-triazaundecane- 1,11-dicarboxylic acid-bis(t-butylester)]-lysine-[1 -(4-perfluorooctylsulfonyl)-piperazine-]-amide,
Gd complex g (15.43 mmol) of the title compound of Example 6b, 1.78 g (15.43 mmol) of N- hydroxysuccinimde, 1.48 g (35 mmol) of lithium chloride and 9.72 g (15.43 mmol) of 1,4,7- tris(carboxylatomethyl)-10-(3 -aza-4-0xo0-5-methyl-5yl)-pentanoic acid-1,4,7,1 0- tetraazacyclododecane, Gd complex are dissolved in 150 ml of dimethyl sulfoxide while being heated slightly. At 10°C, 5.16 g (25 mmol) of N,N-dicyclohexylcarbodiimide is added, and it is then stirred overnight at room temperature. The solution is poured into 2500 ml of acetone and stirred for 10 minutes. The precipitated solid is filtered off and then purified by chromatography (silica gel RP-18, mobile solvent: gradient that consists of water/ethanol/acetonitrile).
Yield: 22.94 g (78% of theory) of a colorless solid.
~~ 84003 . | /1947 ® 9... content: 7.9%
Elementary analysis (relative to anhydrous substance):
Cld: C4222 H5.29 F16.95 Gd8.25 N8.82 S1.68
Fnd: C 42.15 H5.41 F 16.87 Gd 8.13 N8.70 S1.60
Example 6d 6-N-[1,4,7-Tris(carboxylatomethyl)-1,4,7,1 0-tetraazacyclododecane-10-(3-aza-4-oxo-5-methyl- 5-yl)-pentanoyl)]-2-N-[6-carbonylmethyl-3,9-bis(carboxylatomethyl)-3,6,9- triazaundecanedicarboxylic acid-carboxy-11-carboxylato-2]-lysine-[1 -(4-perfluorooctylsulfonyl)- piperazine]-amide, digadolinium complex, sodium salt g (10.49 mmol) of the title compound of Example 6c is dissolved in 200 ml of trifluoroacetic acid. It is stirred for 60 minutes at room temperature. It is evaporated to the dry state in a vacuum, and the residue is dissolved in 150 ml of water. 1.90 g (5.25 mmol) of gadolinium oxide is added, and it is stirred for 5 hours at 80°C. It is allowed to cool to room temperature and set at pH 7.4 with sodium hydroxide solution. The solution is evaporated to the dry state in a vacuum and purified on silica gel RP-18 (mobile solvent: gradient that consists of water/ethanol/acetonitrile).
Yield: 11.89 g (61% of theory) of a colorless, amorphous solid.
Water content: 10.2%
Elementary analysis (relative to anhydrous substance):
Cld: C32.97H3.47F17.39Gd 16.93 N9.05Na 1.24 S 1.73
Fnd: C 32.90 H3.53F 17.31 Gd 16.87 N 8.92 Na 1.33 S 1.67 y ~ 8200371947 © ©. 3,6-Bis(benzyloxy)-3oxa-hexanoic acid-t-butyl ester 100 g (376.2 mmol) of 1,2-Di-O-benzyl-glycerol [produced according to Chem. Phys.
Lipids (1987), 43(2), 113-27] and 5 g of tetrabutylammonium hydrogen sulfate are dissolved in a mixture that consists of 400 ml of toluene and 200 ml of 50% aqueous sodium hydroxide solution. At 0°C, 78 g (400 mmol) of 2-bromoacetic acid-t-butylester is added in drops over 30 minutes, and it is then stirred for 3 hours at 0°C. The organic phase is separated, dried on : magnesium sulfate and evaporated to the dry state in a vacuum. The residue is chromatographed on silica gel (mobile solvent: n-hexane/acetone = 20:1).
Yield: 133.4 g (94% of theory) of a colorless oil.
Elementary analysis:
Cld: C71.48 H7.82
Fnd: C71.61 H 7.92
Example 7h 5,6-Bis(benzyloxy)-3-oxa-hexanoic acid 130 g (336.4 mmol) of the title compound of Example 7a is dissolved in 200 ml of dichloromethane, and 100 ml of trifluoroacetic acid is added at 0°C. It is stirred for 4 hours at room temperature and then evaporated to the dry state. The residue 1s crystallized from pentane/diethyl ether.
Yield: 102.2 g (92% of theory) of a waxy solid
Elementary analysis:
Cd: C 69.07 H6.71
Fnd: C 69.19 H 6.82
CL 82003/1947 ®o 0. 6-N-Benzvloxycarbonyl-2-N-[1,4,7-tris(carboxylatomethyl)1,4,7.1 0O-tetraazacyclododecane-10- (pentanoyl-3-aza-4-0x0-5-methyl-5-yl)]-lysine-[1 -(4-perfluorooctylsulfonyl)-piperazine]-amide,
Gd complex 50 g (60.20 mmol) of the title compound of Example lc, 6.93 g (60.20 mmol) of N- hydroxysuccinimide, 5.09 g (120 mmol) of lithium chloride and 37.91 g (60.20 mmol) of 1,4,7- tris(carboxylatomethyl)-1,4,7,1 0-tetraazacyclododecane- 10-pentanoyl-3-aza-4-0xo-5-methyl- 5yl), Gd complex, are dissolved in 400 ml of dimethyl sulfoxide while being heated slightly. At 10°C, 20.63 g (100 mmol) of N,N-dicyclohexylcarbodiimide is added, and it is then stirred overnight at room temperature. The solution is poured into 3000 ml of acetone and stirred for 10 minutes. The precipitated solid is filtered off and then purified by chromatography (silica gel
RP-18, mobile solvent: gradient that consists of water/ethanol/acetonitrile).
Yield: 75.53 g (87% of theory) of a colorless solid.
Water content: 10.1%
Elementary analysis (relative to anhydrous substance):
Cld: C37.48 H3.84 F22.39 Gd 10.90 N 8.74 §2.22
Fnd: C37.39 H4.02 F22.29 Gd 10.75 N 8.70 S222
Example 7d 2-N-[1 4 7-Tris(carboxylatomethyl)- 1,4,7,10-tetraazacyclododecane-1 0-(pentanoyl-3aza-d-oxo-
Smethyl-5yl]-lysine-[ 1-(4-perfluorooctylsulfonyl)-piperazine]-amide, Gd complex 70 g (48.53 mmol) of the title compound of Example 7c is dissolved in 500 ml of water/100 ml of ethanol, and 5 g of palladium catalyst (10% Pd/C) is added. Itis hydrogenated at room temperature. Catalyst is filtered out, and the filtrate is evaporated to the dry state in a vacuum.
Yield: 63.5 g (quantitative) of a colorless solid.
r 8200371947 ® Q... content: 9.8%
Elementary analysis (relative to anhydrous substance):
Cld: C37.48 H3.84 F22.39 Gd 10.90 N 8.74 §2.22
Fnd: C37.39 H4.03 F22.31 Gd 10.78 N 8.65 S2.20
Example 7¢ 6-N-[5,6-Bis(benzyloxy)-3-oxahexanoyl]-2-N-[1 ,4.7-tris(carboxylatomethyl)-1,4,7,1 0- tetraazacyclododecane-1 0-(pentanoyl-3-aza-4-oxo-5-methyl-5yl)]-lysine-[1-(4- perfluorooctylsulfonyl)-piperazine]-amide, Gd complex g (7.64 mmol) of the title compound of Example 7d, 3.30 g (10 mmol) of the title : compound of Example 7b, 0.85 g (20 mmol) of lithium chloride and 1.15 g (10 mmol) of N- hydroxysuccinimide are dissolved in 150 ml of dimethyl sulfoxide while being heated slightly.
At 10°C, 3.10 g (15 mmol) of N,N'-dicyclohexylcarbodiimide is added, and it is stirred for 8 hours at room temperature. The reaction solution is poured into 2000 ‘ml of acetone, and the deposited precipitate is isolated. The is purified on silica gel RP-18 (mobile solvent: gradient that consists of water/ethanol/acetonitrile).
Yield: 11.14 g (90% of theory) of a colorless, amorphous solid.
Water content: 4.3%
Elementary analysis (relative to anhydrous substance):
Cld: C 41.51 H429 F19.93 N7.78 Gd 9.70 S1.98
Fnd: C 41.45 H4.38 F19.84 N7.70 Gd 9.58 S1.90
8400G3/ 1847 ® © 6-N-(5,6-Dihydroxy-3-oxahexanoyl)-2-N-[1 4,7-tris-carboxylatomethyl)-1,4,7,10- tetraazacyclododecane-1 0-pentanoyl-3-aza-4-o0xo-5-methyl-5-y1)]-lysine [1-(4- perfluorooctylsulfonyl)-piperazine]-amide, Gd complex g (6.17 mmol) of the title compound of Example 7e is dissolved in 200 ml of ethanol, and 3 g of palladium-catalyst (10% Pd/C) is added. It is hydrogenated at room temperature.
Catalyst is filtered out, and the filtrate is evaporated to the dry state in a vacuum. Yield: 8.89 g (quantitative) of a colorless solid.
Water content: 3.1%
Elementary analysis (relative to anhydrous substance):
Cld: C35.03 H3.99 F22.42 Gd 10.92 N 8.75 §2.23
Fnd: C 34.95 H4.12 F22.30 Gd 10.78 N 8.71 S2.18
Example 8a 6-N-Benzyloxycarbonyl-2-N[-5 ,6-bis(benzyloxy)-3-oxa-hexanoyl]-lysine-[1-(4- perfluorooctylsulfonyl)-piperazine]-amide 9.28 g (45 mmol) of N,N-dicyclohexylcarbodiimide is added at 0°C to a solution that consists of 20 g (24.08 mmol) of the title compound of Example lc, 9.91 g (30 mmol) of the title compound of Example 7b and 3.45 g (30 mmol) of N-hydroxysuccinimide, dissolved in 100 ml of dimethylformamide. It is stirred for 3 hours at 0°C, then overnight at room temperature.
Precipitated urea is filtered out, the filtrate is evaporated to the dry state in a vacuum, and it is chromatographed on silica gel (mobile solvent: dichloromethane/ethanol = 20:1). Yield: 24.50 g (89% of theory) of a viscous oil.
Elementary analysis:
Cld: C4729 H4.14 F 28.26 N4.90 S 2.81
Fnd: C 47.14 H4.26 F28.17 N491 §2.69
®e 0 2-N-(5,6-Dihydroxy-3-oxahexanoyl)-lysine-[1-(4-perfluorooctylsulfonyl)-piperazine}-amide 20 g (17.5 mmol) of the title compound of Example 8a is dissolved in 300 ml of ethanol, and 5 g of palladium-catalyst (10% Pd/C) is added. It is hydrogenated at room temperature.
Catalyst is filtered out, and the filtrate is evaporated to the dry state in a vacuum.
Yield: 17.65 g (quantitative) of a colorless solid.
Elementary analysis:
Cld: C44.05 H4.10 F 32.02 N5.55 S3.18
Fnd: C4396 H4.21 F31.94 N548 S3.24
Example 8c 6-N-[1 4.7-Tris(carboxylatomethyl)-1 ,4,7,10-tetraazacyclododecane-10-(pentanoyl-3-aza-4-oxo- 5-methyl-5yl)]-lysine-| -(4-perfluorooctylsulfonyl)-piperazine]-amide, Gd complex g (14.87 mmol) of the title compound of Example 8b, 1.73 g (15 mmol) of N-hydroxy- succinimide, 1.27 g (30 mmol) of lithium chloride and 9.48 g (15 mmol) of 1,4,7- tris(carboxylatomethyl)-1 0-(3-aza-4-o0x0-5-methyl-5-yl)-pentanoic acid-1,4,7,10- tetraazacyclododecane, Gd complex, are dissolved in 100 ml of dimethyl sulfoxide while being heated slightly. At 10°C, 5.16 g (25 mol) of N,N-dicyclohexylcarbodiimide is added, and it is then stirred overnight at room temperature. The solution is poured into 1500 ml of acetone and stirred for 10 minutes. The precipitated solid is filtered off and then purified by chromatography : (silica gel RP-18 mobile solvent: gradient that consists of water/ethanol/acetonitrile).
Yield: 19.28 g (80% of theory) of a colorless solid.
Water content: 10.3%
x 2003/1947 ® _ analysis (relative to anhydrous substance):
Cld: C41.51 H4.29 F19.93 Gd 9.70 N7.78 S1.98
Fnd: C 41.37 H4.40 F 19.88 Gd 9.58 N 7.67 S 1.85
Example 9a 6-N-Benzyloxycarbonyl-2-N-[2,6-N,N'-bis(benzyloxycarbonyl)-lysyl]-lysine-[ 1-(4- perfluorooctylsulfonyl)-piperazine]-amide g (24.08 mmol) of the title compound of Example 1c and 2.53 g (25 mmol) of triethylamine are dissolved in 200 ml of tetrahydrofuran (THF), and 14.46 g (27 mmol) of di-
N,N'-Z-lysine paranitrophenol ester is added. It is stirred for 5 hours at 50°C. It is evaporated to the dry state in a vacuum, and the residue is chromatographed on silica gel.
Mobile solvent: dichloromethane/methanol = 20:1).
Yield: 28.07 g (95% of theory) of a colorless solid.
Elementary analysis:
Cld: C46.99 H4.19 F26.32 N6.85 S261 : ~ Fnd: C 47.08 H4.32 F26.21 N6.75 S2.54
Example 9b 2-N-(Lysyl)-lysine-[1-(4-perfluorooctylsulfonyl)-piperazine}-amide, trihydrobromide 100 ml of hydrobromic acid in glacial acetic acid (48%) is added to 25 g (20.37 mmol) of the title compound of Example 9a, and it is stirred for 2 hours at 40°C. It is cooled to 0°C, 1500 : ml of diethyl ester is added in drops, and the precipitated solid is filtered off. After drying ina vacuum (60°C), 21.52 g (99% of theory) of a slightly yellow-colored, crystalline solid is obtained.
so %2003/1947 ® Qu analysis:
Cld: C27.01 H3.40 Br2246 F30.26 N7.87 S3.00
Fnd: C 26.92 H 3.53 Br22.15 F30.14 N7.69 S2.87
Example 9¢ 6-N-[1,4,7-Tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecane-10-(pentanoyl-3-aza-4-oxo- 5-methyl-5y1)]-2-N-[2,6-N,N"-bis[1 ,4,7-tris carboxylatomethyl)-1 4.7, 10-tetrazacyclododecane- 10-(pentanoyl-3-aza-4-oxo-5-methyl-5-y1)]-lysyl]-lysine-[ 1 -(4-perfluorooctylsulfonyl)- piperazine]-amide, trigadolinium complex 31.49 g (50 mmol) of 1,4,7-tris(carboxylatomethyl)-10-(3-aza-4-oxo0-5-methyl-5-yl)- pentanoic acid, Gd complex 6.91 g (60 mmol) of N-hydroxysuccinimide and 4.24 g (100 mmol) of lithium chloride are dissolved in 350 ml of dimethyl sulfoxide while being heated slightly. At 10°C, 16.51 g (80 mmol) of N,N-dicyclohexylcarbodiimide is added, and it is stirred for 5 hours at 10°C. 10g (9.37 mmol) of the title compound of Example 9b and 3.03 g (30 mmol) of triethylamine are added to this mixture, and it is stirred for 12 hours at 60°C. It is allowed to cool to room temperature, and the mixture is poured into 3000 ml of acetone. The deposited precipitate is filtered off, purified on silica gel RP-18 (mobile solvent: gradient that consists of water/ethanol/acetonitrile).
Yield: 16.7 g (67% of theory) of a colorless solid.
Water content: 7.9% }
Elementary analysis (relative to anhydrous substance):
Cld: C 36.58 H4.43 F 12.14 Gd 17.74 N 11.06 S 1.14
Fnd: C 36.47 H4.54 F 12.03 Gd 17.65 N 10.95 S121
51 8400371947 oo 0 1,7-Bis(benzyloxycarbonyl)-4-(3,6.9.12,15-pentaoxahexadecanoyl)-1.4,7.10- tetraazacyclododecane 2473 ¢g (100 mmol) of EEDQ (2-ethoxy-1,2-dihydroquinoline-1-carboxylic acid ester) is added at 0°C to 18.13 g (68.1 mmol) of 3,6,9,12,15-pentaoxahexadecanoic acid and 30 g (68.1 mmol) of 1,7-di-Z-cyclene produced according to Z. Kovacs and A. D. Sherry, J. Chem. Soc.
Chem. Commun. (1995), 2, 185, in 300 ml of tetrahydrofuran, and it is stirred overnight at room temperature. It is evaporated to the dry state in a vacuum and chromatographed on silica gel (mobile solvent: dichloromethane/methanol = 20:1).
Yield: 19.13 g (42% of theory) of a colorless solid.
Elementary analysis:
Cld: C61.03 H7.61 N&.13
Fnd: C6092 H7.75 N 8.04
Example 10b 1,7-Bis(benzyloxycarbonyl)-4-(3,6,9,12,1 5-pentaoxahexadecanoyl)-1 0-(2H,2H,4H,5H,5H-3-0xa- perfluorotridecanoyl)-1,4,7,10-tetraazacyclododecane 12.36 g (50 mmol) of EEDQ (2-ethoxy-1,2-dihydroquinoline-1-carboxylic acid ethyl ester) is added at 0°C to 18 g (26.91 mmol) of the title compound of Example 10a and 14.05 g (26.91 mmol) of 2H 2H 4H,4H,5H,5H-3-0xa-perfluorotridecanoic acid, produced according to
DE 19603033, in 300 ml of tetrahydrofuran, and it is stirred overnight at room temperature. It is evaporated to the dry state in a vacuum and chromatographed on silica gel (mobile solvent: dichloromethane/methanol = 20:1). :
Yield: 21.51 g (67% of theory) of a colorless solid .
2 - 82003/1947 ® ®....o analysis:
Cld: C4732 H4.82 F 27.07 N4.70
Fnd: C 47.26 H5.01 F26.94 N4.59
Example 10¢ 1-(3,6,9,12,15-Pentaoxahexadecanoyl)-7-(2H,2H,4H.4H,5H,SH-3-oxaperfluorotridecanoyl)- 1,4,7,10-tetraazacyclododecane 20 g (16.77 mmol) of the title compound of Example 1d is dissolved in 200 ml of ethanol, and 2.5 g of palladium catalyst (10% Pd/C) is added. It is hydrogenated at room temperature. Catalyst is filtered out, and the filtrate is evaporated to the dry state in a vacuum.
Yield: 15.5 g (quantitative) of a colorless solid.
Elementary analysis:
Cld: C 40.27 H4.90 F 34.93 N 6.06
Fnd: C 40.15 H4.99 F 34.87 N5.94
Example 10d 1,7-Bis(1,4,7-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecane- 1 0-(pentanoyl-3-aza-4- o0xo-5-methyl-5-y1)]-4-(3,6,9,12,15-pentaoxahexadecanoyl)-10-(2H,2H,4H,4H,5H,5H-3- oxaperfluorotridecanoyl)- 1,4,7,1 0-tetraazacyclododecane, Gd complex g (16.22 mmol) of the title compound of Example 10c, 4.60 g (40 mmol) of N- hydroxysuccinimide, 3.39 g (80 mmol) of lithium chloride and 25.19 g (40 mmol) of 1,4,7-tris- (carboxylatomethyl)-10-(3-aza-4-oxo-5-methyl-5yl)pentanoic acid, Gd complex, are dissolved in: 300 ml of dimethyl sulfoxide while being heated slightly. At 10°C, 24.73 g (100 mmol) of
EEDQ is added, and it is then stirred overnight at room temperature. The solution is poured into 3000 ml of acetone and stirred for 10 minutes.
The precipitated solid is filtered off and then purified by chromatography (silica gel RP-
53 82003/1947 ® 18) 0. solvent: gradient that consists of water/ethanol/acetonitrile).
Yield: 19.86 g (57% of theory) of a colorless solid
Water content: 11.3%
Elementary analysis (relative to anhydrous substance):
Cld: C 38.58 H4.74 F 15.04 Gd 14.64 N9.13
Fnd: C 38.47 H491 F 14.95 Gd 14.57 N 9.04
Example lla 3,5-Dinitrobenzoic acid-1-[(4-perfluorooctylsulfonyl)-piperazine]-amide
A solution that consists of 8.76 g (38 mmol) of 3,5-dinitrobenzoyl chloride in 55 ml of "dichloromethane is added in drops at 0°C to 20 g (35.2 mmol) of perfluorooctylsulfonyl- piperazine and 8.1 g (80 mmol) of triethylamine, dissolved in 200 ml of dichloromethane, and it is stirred for 3 hours at 0°C. 200 ml! of 5% aqueous hydrochloric acid is added, and it is stirred for 5 minutes at room temperature. The organic phase is separated, dried on magnesium sulfate and evaporated to the dry state in a vacuum. The residue is chromatographed on silica gel (mobile solvent: dichloromethane/acetone = 15:1).
Yield: 24.96 g (93% of theory) of a colorless solid.
Elementary analysis:
Cld: C29.35 H1.45 F42.37 N7.35 S421
Fnd: C29.28 H1.61 F42.15 N725 S4.15
Example 11h 3,5-Diaminobenzoic acid-[1 ~(4-perfluorooctylsulfonyl)-piperazine}-amide g (26.23 mmol) of the title compound of Example 11a is dissolved in 400 ml of ethanol, and 6 g of palladium catalyst (10% Pd/C) is added. Itis hydrogenated at room se 5400371947 ® ene Catalyst is filtered out. and the filtrate is evaporated to the dry state in a vacuum.
Yield: 18.43 g (quantitative) of a cream-colored solid.
Elementary analysis:
Cld: C32.49 H2.15 F4598 N 7.98 S457
Fnd: C32.29 H2.35 F45.69 N7.81 S4.40
Example 11¢ 3,5-N,N'-Bis[1,4,7-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecane- 10-(pentanoyl-3-aza- 4-0x0-5-methyl-5-yl-)]-benzoic acid-[1-(4-perfluorooctyl-sulfonyl)-piperazine]-amide, Gd complex g (14.24 mmol) of the title compound of Example 11b, 3.45 g (30 mmol) of N- hydroxysuccinimide, 2.54 g (60 mmol) of lithium chloride and 18.89 g (30 mmol) of 1,4,7-tris- (carboxylatomethyl)-10-(3-aza-4-oxo0-5-methyl-5yl)-pentanoic acid, Gd complex, are dissolved in 200 ml of dimethyl sulfoxide while being heated slightly. At 10°C, 10.32 g (50 mmol) of N,N-dicyclohexylcarbodiimide is added, and it is then stirred overnight at room temperature. The solution is poured into 2000 ml of acetone and stirred for 10 minutes. The precipitated solid is filtered off and then purified by chromatography (silica gel RP-18, mobile solvent: gradient that consists of water/ethanol/acetonitrile).
Yield: 19.74 g (72% of theory) of a colorless solid.
Water content: 11.8%
Elementary analysis (relative to anhydrous substance):
Cld: C 35.55 H3.72 F16.77 Gd 16.33 N 10.18 S 1.67
Fnd: C 35.48 H3.84 F16.58 Gd 16.24 N 10.07 S1.58
® 3 12 a) 3-Oxa-2H.2H,4H 4H,5H.5H-perfluorotridecanecarboxylic acid-t-butyl ester 25.0 g (53.8 mmol) of 1H,1H,2H,2H-perfluoro- 1-decanol [commercially available from the Lancaster Company] 1s dissolved in 250 ml of absolute toluene and mixed at room temperature with a catalytic amount (about 0.75 g) of tetra-n-butyl-ammonium hydrogen sulfate.
Then, a total of 7.55 g (134.6 mmol; 2.5 equivalents relative to the alcohol component used) of fine-powder potassium hydroxide powder is added at 0°C, followed by 15.73 g (80.7 mmol; 1.5 equivalents relative to the alcohol component used) of bromoacetic acid-tert-butyl ester, and it is allowed to stir for 2 more hours at 0°C. The reaction solution that is thus obtained is stirred for 12 more hours at room temperature and is mixed with a total of 500 ml of ethyl acetate and 250 ml of water for the purposes of working-up. The organic phase is separated and washed twice with water. After the organic phase has dried on sodium sulfate, salt is suctioned out, and the solvent is drawn off in a vacuum. The remaining oily residue is purified as an eluant on silica gel with use of ethyl acetate/hexane (1:10) as an eluant.
Yield: 26.3 g (84.6% of theory) of the above-mentioned title compound as a colorless and strongly viscous oil.
Elementary analysis:
Cld: (C33.23 H2.61 F 55.85
Fnd: C33.29 H2.61 F 5590 b) 3-Oxa-2H,2H,4H,4H,5H, 5H-perfluorotridecanecarboxylic acid 20.0 g (34.58 mmol) of the title compound of Example 12a) is suspended in 200 ml of a mixture, consisting of methanol and 0.5 molar sodium hydroxide solution in a ratio of 2:1 while being stirred at room temperature, and then it is heated to 60°C. After a reaction time of 12 hours at 60°C, the now clear reaction mixture is neutralized for working-up by mixing with
Amberlite® IR 120 (H form)-cation exchanger resin, exchanger is suctioned out, and the thus
~~ B84UUY/194/ ® - methanolic-aqueous filtrate is drawn off in a vacuum until a dry state is reached. The obtained amorphous-oily residue is purified as an eluant on silica gel with use of ethyl acetate/n- hexane (1:3).
Yield: 16.0 g (88.6% of theory) of the above-mentioned title compound as colorless and strongly viscous oil.
Elementary analysis:
Cld: C27.60 H1.55 F 61.85
Fnd: C 27.58 H 1.36 F 61.90 c) 1,7-Bis{[1,4,7-tris(carboxylatomethyl)-10-(3-aza-4-oxo-5-methyl-5-yl-pentanoyl)]- 1,4,7,10-tetraazacyclododecane} -diethylenetriamine, digadolinium-complex 2.48 g [(3.94 mmol); 2.05 molar equivalents relative to the diethylene triamine used] of the Gd complex, described in the Patent Application DE 197 28 954 C1 under Example 31h), of 10-(4-carboxy- 1-methyl-2-oxo-3-azabutyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid, and 167 mg of anhydrous lithium chloride (3.94 mmol) are dissolved at 40°C in 40 ml of absolute dimethyl sulfoxide while being stirred, and mixed with a total of 453 mg (3.94 mmol) of
N-hydroxysuccinimide at this temperature. After cooling to room temperature, the thus obtained reaction solution is mixed with 814 mg (3.946 mmol) of N,N'-dicyclohexylcarbodiimide and stirred for 2 hours at room temperature. The suspension of active ester that is obtained is then mixed with 198.3 mg (1.92 mmol) of diethylenetriamine, dissolved in 5 ml of absolute dimethyl sulfoxide, mixed and stirred for 12 hours at room temperature. For the purpose of working-up, the reaction mixture is mixed with sufficient acetone until complete precipitation of the above- mentioned title compound is achieved, the precipitate is suctioned off, dried, taken up in water, insoluble dicyclohexyl urea is filtered out, and the filtrate is desalinated on an AMICON® yM-3 ultrafiltration membrane (cut-off 3000 Da), and low-molecule components are removed. The retentate is then freeze-dried.
® J 1.85 g (72.7% of theory) as a colorless lvophylizate.
H>O content (Karl-Fischer): 3.89%.
Elementary analysis (relative to anhydrous substance):
Cld: C38.03 H5.24 N 13.73 Gd 23.71
Fnd: C37.98 H5.20 N 13.69 Gd 23.78 d) 1 ,7-Bis{ [1,4,7-tris(carboxylatomethyl)-1 0-(3-aza-4-ox0-5-methyl-5-yl-pentanoyl)]- 1,4,7,10-tetraazacyclododecane } -4-(3-oxa-2H,2H,4H,4H,5H,5 H-perfluorotridecanoyl)- diethylenetriamine, digadolinium complex 1.27 g (2.44 mmol) of the title compound of Example 12b), dissolved in a mixture that consists of 15 ml of tetrahydrofuran and 15 ml of dimethyl sulfoxide, is added drop by drop to a solution of 3.23 g (2.44 mmol) of the title compound of Example 12¢), in a mixture that consists of 30 ml of dimethyl sulfoxide and 3 ml of tetrahydrofuran, at 50°C and under nitrogen atmosphere. Then, a total of 1.80 g (3.66 mmol) of EEDQ [2-ethoxy-1-ethoxycarbonyl-1,2- dihydroquinoline) is added in portions at 0°C and allowed to stir overnight at room temperature.
The reaction solution that is obtained is then mixed with sufficient acetone until the precipitation of the above-mentioned title compound is completed, the precipitate is suctioned off, dried, taken up in water, insoluble components are filtered out, and the filtrate is ultrafiltered on an
AMICON® YM-3 ultrafiltration membrane (cut-off, 3000 Da), which is used both for complete desalination and for purification of the title compound of low-molecular components. The retentate is then freeze-dried.
Yield: 3.54 g (79.4% of theory) as a colorless lyophilizate.
H2O-content (Karl-Fischer): 5.87%.
® _S— analysis (relative to anhydrous substance):
Cld: 33.43 H4.07 N9.95 F 17.64 Gd 17.18
Fnd: C3542 H4.01 N9.89 F 17.67 Gd 17.18
Example 13 a) 2-N-Trifluoroacetyl-6-N-benzocarbonyl-L-lysine -_ 100.0 g (356.7 mmol) of 6-N-benzyloxycarbonyl-L-lysine is dissolved in a mixture that consists of 1000 ml of trifluoroacetic acid ethyl ester and 500 ml of ethanol, and it is stirred for 24 hours at room temperature. It is evaporated to the dry state, and the residue is crystallized from diisopropyl ether.
Yield: 128.9 g (96% of theory) of a colorless, crystalline powder.
Melting point: 98.5°C
Elementary analysis:
Cld: C51.07 H5.09 N 7.44 F 15.14
Fnd: C51.25 H5.18 N 7.58 F 15.03 b) 2-N-Trifluoroacetyl-6-N-benzyloxycarbonyl-L-lysine [1-(4-perfluorooctylsulfonyl)- piperazine}-amide 164.2 g (0.664 mmol) of EEDQ (2-ethoxy-1,2-dihydroquinoline-1-carboxylic acid ethyl ester) is added at 0°C to 125.0 g (332.0 mmol) of the title compound of Example 1a) and 188.7 g (332.0 mmol) of 1-perfluorooctylsulfonylpiperazine (produced according to DE 19603033) in 750 ml of tetrahydrofuran, and it is stirred overnight at room temperature. It is evaporated to the dry state in a vacuum and chromatographed on silica gel (mobile solvent: dichloromethane/methanol = 20:1).
Yield: 286.0 g (93% of theory) of a colorless solid.
Melting point: 92°C.
~~ 8400371947 ® J analysis:
Cld: C36.30 H2.83 N6.05 F41.01 S346
Fnd: C 36.18 H2.94 N 598 F 40.87 S3.40 c) 6-N-Benzyloxycarbonyl-L-lysine-{1 (4-perfluorooctylsulfonyl)-piperazine]-amide
Ammonia gas is introduced at 0°C for one hour into a solution that consists of 280.0 g (302.2 mol) of the title compound of Example 1b in 2000 ml of ethanol. It is then stirred for 4 hours at 0°C. It is evaporated to the dry state, and the residue is absorptively precipitated from water. The solid is filtered off and dried in a vacuum at 50°C.
Yield: 243.5 g (97.0% of theory) of an amorphous solid.
Elementary analysis:
Cld: C37.60 H3.28 N6.75 F 38.89 S3.86
Fnd: C 37.55 H3.33 N6.68 F 38.78 S 3.81 d) L-Lysine-[1-(4-perfluorooctylsulfonyl)-piperazine]-amide
In 1000 ml of ethanol, 200.0 g (240.8 mmol) of the compound produced under 13c¢) is dissolved, mixed with 5.0 g of Pearlman's catalyst (Pd 20%, C) and hydrogenated at room temperature under a hydrogen atmosphere (1 atm) until no more hydrogen uptake can be observed. Catalyst is suctioned out, thoroughly rewashed with ethanol (three times, with about 100 ml in each case) and evaporated to the dry state in a vacuum. The title compound is obtained as a strongly viscous and yellow-colored oil.
Yield: 162.5 g (96.9% of theory).
Elementary analysis:
Cld: C31.04 H3.04 N 8.05 F46.38 S4.60
Fnd: C31.11 H3.09 N 8.08 F46.33 S4.62
60 8400371947 ® e) Q. x {4-[2,3-bis-(N,N-bis(t-butyloxycarbonylmethyl)-amino)-propyl]-phenyl}-3- oxa-propionyl-L-lysine-{ 1-(4-perfluorooctylsulfonyl)-piperazine]-amide 5.25 g (7.72 mmol) of the 4-[2,3-bis-(N,N-bis(t-butyloxycarbonylmethyl)-amino)- propyl]-phenyl} -3-oxa-propionic acid and 781.0 mg (7.72 mmol) of triethylamine are dissolved in 50 ml of methylene chloride. At-15°C, a solution that consists of 1.16 g (8.5 mmol) of isobutyl chloroformate is added in drops in 10 ml of methylene chloride within 5 minutes, and it is stirred for another 20 minutes at -15°C. Then, the solution is cooled to -25°C, and a solution that consists of 2.68 g (3.86 mmol) of the title compound of Example 13d) and 2.12 g (21.0 mmol) of triethylamine, in 70 ml of tetrahydrofuran, is added in drops within 30 minutes and stirred subsequently for 30 minutes at -15°C, and then stirring is continued overnight at room temperature. For working-up, the solvent is taken up in a vacuum, and the remaining oily residue is taken up in 250 ml of chloroform. The chloroform phase is extracted twice with 100 ml each of a 10% aqueous ammonium chloride solution, the organic phase is dried on magnesium sulfate and evaporated to the dry state in a vacuum. The residue is chromatographed on silica gel (mobile solvent: methylene chloride/ethanol = 20:1).
Yield: 5.37 g (68.8% of theory) of a colorless and very viscous oil.
Elementary analysis:
Cld: C5227 H6.43 N 5.54 F 1597 S1.59
Fnd: C 52.22 H6.51 N 549 F 15.99 S1.63 f) 6N-2N-Bis- {4-[2,3-bis-(N,N-bis(carboxylatomethyl)-amino)-propyl]-phenyl}-3-oxa- propionyl-L-lysine-[ 1-(4-perfluorooctylsulfonyl)-piperazine]-amide, octa-sodium salt 5.0 g (2.47 mmol) of the title compound of Example 13e) is dissolved in 60 ml of : absolute dichloromethane. Then, it is mixed drop by drop at 0°C with a total of 75 ml of trifluoroacetic acid. After a reaction time of 12 hours at room temperature, it is evaporated to the dry state in a vacuum. The remaining residue is mixed with 100 ml of water and again drawn off
. ~ 8400371947 ® ina oe until the material is dry. The thus obtained residue is dissolved in 200 ml of distilled water, and the aqueous product solution of the above-mentioned title compound is extracted twice with 60 mi of diethyl ether in each case. The resulting aqueous product solution is made up by mixing with water to a total volume of 300 ml, insoluble components are filtered off, and the filtrate is ultrafiltered on an AMICON® YM-3 ultrafiltration membrane (cut-off 3000 Da), which is used both for complete desalination and for purification of the title compound of low-molecular components. The retentate is made up to a total volume of 200 ml by mixing with water, and the pH of this solution is then set at 10.0 with 15% sodium hydroxide solution.
The basic, aqueous product solution is subsequently freeze-dried. 4.0 g (92.8% of theory) of the title compound is obtained in the form of the octa-sodium salt as an amorphous lyophilizate.
Water content: 5.37%
Elementary analysis (relative to anhydrous substance):
Cld: C 38.46 H3.28 N6.41 F 1847 S1.83 Na10.52
Fnd: C 38.42 H3.31 N6.39 F18.51 S1.87 Nal10.38 2) 6N-2N-Bis-{4-[2,3-bis-(N _N-bis(carboxymethyl)-amino)-propyl]-phenyl}-3-oxa- propionyl-L-lysine-[ 1-(4-perfluorooctylsulfonyl)-piperazine]-amide, di-manganese complex, tetrasodium salt 1.94 g (1.11 mmol) of the title compound of Example 13f) is dissolved in 100 ml of distilled water, and the resulting solution is brought to a pH of 4.0 by mixing with 1 molar aqueous hydrochloric acid. At 80°C, it is now mixed in portions with 0.25 g (2.22 mmol) of manganese(1l) carbonate. Then, the thus obtained reaction solution is refluxed for 5 hours. After cooling to room temperature, the pH of the aqueous product solution is set at 7.2 by mixing with
IN sodium hydroxide solution while being stirred vigorously and is desalinated via an
AMICON® YM-3 ultrafiltration membrane (cut-off 3000 Da), and low-molecular components
N ~ 840037194 ® are oe. The retentate is then freeze-dried.
Yield: 1.80 g (92.0% of theory) of the title compound as a colorless lyophilizate.
HO content (Karl-Fischer): 7.28%.
Elementary analysis (relative to anhydrous substance):
Cld: C38.07H3.25F18.28 Mn 6.22 N 6.34 Na5.20 S 1.81
Fnd: C38.01 H3.29F 18.29 Mn 6.21 N 6.36 Na 5.28 S 1.78 :
Example 14 : a) 6-N-(Benzyloxycarbonyl)-2-N-[(N-pteroyl)-L-glutaminyl]-lysine-[1-(4- perfluorooctylsulfonyl)-piperazine]-amide g (45.31 mmol) of folic acid is dissolved in 300 ml of dimethyl sulfoxide, and 9.49 g (46 mmol) of N,N-dicyclohexylcarbodiimide is added at 10°C. It is stirred overnight at room temperature. 29.1 g (35 mmol) of the title compound of Example 1c and 20 ml of pyridine are added to this mixture, and it is stirred for 3 hours at 50°C. It is cooled to room temperature, and a mixture that consists of 1500 ml of diethyl ether/1500 ml of acetone is added. The deposited precipitate is filtered off and purified on (RP-18) (mobile solvent = gradient that consists of water/ethanol/tétrahydrofuran).
Yield: 21.59 g (38% of theory) of yellow solid.
Water content: 2.1%
Elementary analysis (relative to anhydrous substance):
Cld: C43.10 H3.54 F25.76 N 11.29 S2.56
Fnd: C 43.02 H3.62 F25.68 N 11.21 S2.48 b) 2-N-[(N-Pteroyl)-L-glutaminyl]-lysine-[1-(4-perfluorooctyisulfonyl)-piperazine}-amide 200 ml of hydrobromic acid in glacial acetic acid (48%) is added to 20 g (15.95 mmol) of
63 8200371947 ® the LS of Example 14a, and it is stirred for 2 hours at 40°C. It is cooled to 0°C, 2000 ml of diethyl ether is added in drops, and the precipitated solid is filtered off. After drying ina vacuum (60°C), 18.96 g (99% of theory) of a yellow-colored, crystalline solid is obtained.
Elementary analysis:
Cld: C 37.01 H3.27 Br6.65 F 26.90 N 12.83 S2.67
Fnd: C 36.91 H3.42 Br6.31 F29.75 N 12.72 S2.56 ¢) 6-N-[1,4,7-Tris(carboxylatomethyl)-1,4,7,1 0O-tetraazacyclododecane-10-(pentanoyl-3-aza-4- oxo0-5-methyl-5yl]-2-N-[(N-pteroyl]-L-glutaminyl]-lysine-{1 -(4-perfluorooctylsulfonyl)- piperazine]-amide, Gd complex 0.92 g (8 mmol) of N-hydroxysuccinimide, 0.68 g (16 mol) of lithium chloride and 5.04 g (8 mmol) of 1,4,7-tris(carboxylatomethyl-10-(3-aza-4-oxo-5-methyl-5-y1)-1,4,7-10- tetraazacyclododecane, Gd complex, are dissolved in 80 ml of dimethyl sulfoxide while being heated slightly. At 10°C, 2.06 g (10 mol) of N,N-dicyclohexylcarbodiimide is added, and it is then stirred for 3 hours at room temperature. 5 g (4.16 mmol) of the title compound of Example 14b and 10 ml of pyridine are added to this reaction solution, and it is stirred overnight at room temperature. The solution is poured into 1000 ml of acetone and stirred for 10 minutes. The precipitated solid is filtered off and then purified by chromatography (silica gel RP-18, mobile solvent: gradient that consists of water/ethanol/acetonitrile). It is dissolved in some water, the pH is set at 7.4 with sodium hydroxide solution and freeze-dried.
Yield: 3.87 g (53% of theory) of a yellow solid. : Water content: 5.8%
Elementary analysis (relative to anhydrous substance):
Cld: C3836 H3.74F 18.42 Gd 8.97 N 12.78 Na 1.31 S 1.83
Fnd: C3828 H3.85F 18.33 Gd 8.85 N 12.69 Na 1.425 1.75
® 3 15 a) 6-N-Benzvloxycarbonyl-2-N=(3,6,9,12-tetraoxatridecanoyl)-lysine[ 1-(4- perfluorooctylsulfonyl)-piperazine]-amide
A solution that consists of 16.85 g (70 mmol) of 3,6,9,12 tetraoxatridecanoic acid chloride in 50 ml of dichloromethane is added in drops at 0°C to 50 g (60.20 mmol) of the title compound of Example 1c and 7.10 g (70 mmol) of triethylamine, dissolved in 350 ml of dichloromethane, and it is stirred for 3 hours at 0°C. 200 ml of 5% aqueous hydrochloric acid is added, and it is stirred for 5 minutes at room temperature. The organic phase is separated, dried on magnesium sulfate and evaporated to the dry state in a vacuum. The residue is chromatographed on silica gel (mobile solvent: dichloromethane/acetone = 15:1).
Yield: 30.94 g (92% of theory) of a colorless, viscous oil.
Elementary analysis:
Cld: C40.63 H4.19 F31.21 N541 S3.10
Fnd: C 40.75 H4.08 F31.29 N5.58 S3.25 b) 2-N-(3,6,9,12-Tetraoxatridecanoyl)-lysine[1 -(4-perfluorooctylsulfonyl)-piperazine]-amide 53.96 g (52.15 mmol) of the title compound of Example 15a is dissolved in 500 ml of ethanol, and 6 g of palladium catalyst (10% Pd/C) is added. It is hydrogenated at room temperature. Catalyst is filtered out, and the filtrate is evaporated to the dry state in a vacuum. .
Yield: 43.0 g (quantitative) of a colorless solid.
Elementary analysis:
Cld: C36.01 H4.14 F35.86 N 6.22 S3.56
Fnd: C 27.60 H5.13 F 39.09 N 6.68 S 3.81
® c) A J 1,4,7-Tris(carboxylatomethyl)-1.4,7,10-tetraazacyclododecane-1 0-(pentanoyl-3-aza-4- oxo-5-methyl-3-y1)]-2-N-(3,6.9,12-tetraoxatridecanoyl)-lysine{ 1 -(4-perfluorooctylsulfonyl)- piperazine]-amide, Gd complex 21.84 g (24.25 mmol) of the title compound of Example 15b, 2.79 g (24.25 mmol) of N- hydroxysuccinimide, 2.12 g (50 mmol) of lithium chloride and 15.27 g (24.25 mmol) of 1,4,7- tris(carboxylatomethyl)-10-[(3-aza-4-0x0-5-methyl-5-vl)]-pentanoic acid]-1,4,7,10- tetraazacyclodecane, Gd complex, are dissolved in 200 ml of dimethyl sulfoxide while being heated slightly. At 10°C, 8.25 g (40 mmol) of N,N-dicyclohexyl-carbodiimide is added, and it then is stirred overnight at room temperature. The solution is poured into 3000 ml of acetone and stirred for 10 minutes. The precipitated solid is filtered off and then purified by chromatography (silica gel RP-18, mobile solvent: gradient that consists of water/ethanol/acetonitrile).
Yield: 28.21 g (81% of theory) of a colorless solid.
Water content: 11.0%
Elementary analysis (relative to anhydrous substance):
Cld: C 36.53 H4.33 F21.36 N8.34 $2.12 Gd 10.40
Fnd: C 31.74 H4.98 F22.39 N 8.69 S2.15 Gd 10.87
Example 16 a) 6-N-Benzyloxycarbonyl-2-N-(propyl-3-sulfonic acid)-lysine[1-(4-perfluorooctyl-sulfonyl)- piperazine]-amide
A solution that consists of 7.33 g (60 mol) of propanesultone in 50 ml of tetrahydrofuran is added in drops at 50°C to 50 g (60.20 mmol) of the title compound of Example lcand 7.10 g (70 mmol) of triethylamine, dissolved in 250 ml of dry tetrahydrofuran, and it is stirred for 3 hours at 60°C. 200 ml of 5% aqueous hydrochloric acid is added, and it is stirred for 5 minutes at room temperature. The organic phase is separated, dried on magnesium sulfate and evaporated to the dry state in a vacuum. The residue is chromatographed on silica gel (mobile solvent:
® sen aneracetont = 15:1).
Yield: 45.16 g (79% of theory) of a colorless, viscous oil.
Elementary analysis:
Cld: C 36.56 H3.49 F33.90 N 588 S6.73
Fnd: C 36.72 H3.35 F33.79 N5.78 §6.75 b) 2-N-(Propyl-3-sulfonic acid)-lysine[1 -(4-perfluorooctylsulfonyl)-piperazine]-amide 49.68 g (52.15 mmol) of the title compound of Example 16a is dissolved in 500 ml of ethanol, and 6 g of palladium catalyst (10% Pd/C) is added. Itis hydrogenated at room temperature. Catalyst is filtered out, and the filtrate is evaporated to the dry state in a vacuum.
Yield: 42.69 g (quantitative) of a colorless solid.
Elementary analysis: i
Cld: C 30.81 H3.32 F39.46 N6.84 S7.83
Fnd: C 30.64 H4.1 F39.29 N6.68 S7.89 c) 6-N-[1,4,7-Tris(carboxylatomethyl)-1,4,7,1 0-tetraazacyclododecane-10-(pentanoyl-3-aza-4- oxo-5-methyl-5-y1)]-2-N-(propyl-3-sulfonic acid)-lysine[ 1-(4-perfluorooctylsulfonyl)- piperazine]-amide, Gd complex 19.85 g (24.25 mmol) of the title compound of Example 16b, 2.79 g (24.25 mmol) of N- hydroxysuccinimide, 2.12 g (50 mmol) of lithium chloride and 15.27 g (24.25 mmol) of 1,4,7- tris(carboxylatomethyl)-10-[(3 -aza-4-0x0-5-methyl-5-yl)]-pentanoic acid]-1,4,7,10- tetraazacyclododecane, Gd complex, are dissolved in 200 ml of dimethyl sulfoxide while being heated slightly. At 10°C, 8.25 g (40 mmol) of N,N-dicyclohexylcarbodiimide is added, and it then is stirred overnight at room temperature. The solution is poured into 3000 ml of acetone and stirred for 10 minutes. The precipitated solid is filtered off and then purified by chromatography
} ~ 8200371947 ® - RP-18, mobile solvent: gradient that consists of water/ethanol/acetonitrile).
Yield: 28.13 g (81% of theory) of a colorless solid.
Water content: 11.0%
Elementary analysis (relative to anhydrous substance):
Cld: C33.27 H3.70 F22.36 N8.73 S4.44 Gd 10.89
Fnd: | C32.41 H3.88 F22.49 N8.69 S4.35 Gd 10.97
Example 17 a) 6-N-Benzyloxycarbonyl-2-N,N-bis(propyl-3-sulfonic acid)-lysine[1-(4- perfluorooctylsulfonyl)-piperazine}-amide
A solution that consists of 14.65 g (120 mmol) of 1,3-propanesultone in 100 ml of tetrahydrofuran is added in drops at 50°C to 50 g (60.20 mmol) of the title compound of Example lc and 12.14 g (120 mmol) of triethylamine, dissolved in 250 ml of dry tetrahydrofuran, and it is stirred for 3 hours at 60°C. 400 ml of 5% aqueous hydrochloric acid is added, it is stirred for 5 minutes at room temperature, mixed with sodium chloride, the organic phase is separated, dried on magnesium sulfate, and it is evaporated to the dry state in a vacuum. The residue is chromatographed on silica gel (mobile solvent: dichloromethane/ acetone = 15:1).
Yield: 52.24 g (81% of theory) of a colorless, viscous oil.
Elementary analysis:
Cld: C35.76 H3.66 F 30.05 N5.21 S8.95
Fnd: C 35.75 H3.55 F30.19 N 5.08 S$9.04 b) 2-N,N Bis(propyl-3-sulfonic acid)-lysine [1-(4-perfluorooctylsulfonyl)-piperazine]-amide 53.74 g (52.15 mmol) of the title compound of Example 17a is dissolved in 500 ml of ethanol, and 6 g of palladium catalyst (10% Pd/C) is added. It is hydrogenated at room
~~ 8200371947 ® one Catalyst is filtered out, and the filtrate is evaporated to the dry state in a vacuum.
Yield: 49.06 g (quantitative) of a colorless solid.
Elementary analysis:
Cld: C30.64 H3.54 F34.33 N596 S10.23
Fnd: C30.69 H3.71 F34.19 N 6.08 S 10.38 ¢) 6-N-[1,4,7-Tris(carboxylatomethyl)-1,4,7,1 O-tetraazacyclododecane-10-(pentanoyl-3-aza-4- oxo-5-methyl-5-yI)]-2-N,N bis(propyl-3-sulfonic acid)-lysine[1 -(4-perfluorooctylsulfonyl)- piperazine]-amide, Gd complex, disodium salt 38.76 g (24.25 mmol) of the title compound of Example 17b, 2.79 g (24.25 mmol) of N- hydroxysuccinimide, 2.12 g (50 mmol) of lithium chloride and 15.27 g (24.25 mmol) of 1,4,7- tris(carboxylatomethyl)-10-[(3-aza-4-0x0-5-methyl-5-yl)]-pentanoic acid]-1,4,7,10- tetraazacyclododecane, Gd complex, are dissolved in 200 ml of dimethyl sulfoxide while being heated slightly. At 10°C, 8.25 g (40 mmol) of N,N-dicyclohexylcarbodiimide is added, and it then is stirred overnight at room temperature. The solution is poured into 3000 ml of acetone, and it is stirred for 10 minutes. The precipitated solid is filtered off, and then purified by chromatography (silica gel RP-18, mobile solvent: gradient that consists of water/ethanol/acetonitrile).
Yield: 31.63 g (81% of theory) of a colorless solid.
Water content: 11.0%
Elementary analysis (relative to anhydrous substance):
Cld: C 32.07 H3.57 F 20.06 N 7.83 $5.97 Gd 9.76 Na 2.86
Fnd: C31.94 H3.48 F20.19N 7.69 S 5.85 Gd 9.87 Na 2.99 os ~ 8800371947 ® 3 18 a) N-Trifluoroacetyl-L-glutamic acid-5-benzy! ester 100 g (421.5 mmol) of L-glutamic acid-5-benzyl ester is dissolved in a mixture that consists of 1000 ml of trifluoroacetic acid ethyl ester/500 ml of ethanol, and it is stirred for 24 hours at room temperature. It is evaporated to the dry state, and the residue is crystallized from diisopropyl! ether.
Yield: 140.47 g (96% of theory) of a colorless, crystalline powder.
Elementary analysis:
Cld: C50.46 H4.23 F 17.10 N 4.20
Fnd: C51.35 H4.18 F 17.03 N4.28 b) 2-N-Trifluoroacetyl-L-glutamic acid-5-benzyl ester-N-bis(2-hydroxyethyl)-amide 8.25 g (40 mmol) of N,N-dicyclohexylcarbodiimide is added at 0°C to a solution that consists of 24.9 g (24.08 mmol) of the title compound of Example 18a, 2.53 g (24.08 mmol) of diethanolamine and 2.77 g (24.08 mmol) of N-hydroxysuccinimide, dissolved in 150 ml of dimethylformamide. It is stirred for 3 hours at 0°C, then overnight at room temperature.
Precipitated urea is filtered out, the filtrate is evaporated to the dry state in a vacuum and chromatographed on silica gel (mobile solvent = dichloromethane/ethanol = 20:1).
Yield: 9.11 g (90% of theory) of a viscous oil.
Elementary analysis:
Cld: C51.43 H5.51 F 13.56 N 6.66
Fnd: C 51.22 HS.41 F13.40 N6.75 ¢) N-Trifluoroacetyl-L-glutamic acid-N bis(2-hydroxyethyl)-monoamide 21.92 g (52.15 mmol) of the title compound of Example 18b is dissolved in 500 ml of
. ~ 8400371947 ® i. and 3 g of palladium catalyst (10% Pd/C) is added. It is hydrogenated at room temperature. Catalyst is filtered out, and the filtrate is evaporated to the dry state in a vacuum.
Yield: 43.0 g (quantitative) of a colorless solid. :
Elementary analysis:
Cld: C40.01 H5.19 F17.26 N 8.48
Fnd: C39.84 H5.13 F17.09 N 8.68 d) Trifluoroacetyl-L-glutamic acid-N-bis(2-hydroxyethyl)-amide-5-[ 1-(4- perfluorooctylsulfonyl)-piperazine]-amide 16.42 g (66.4 mmol) of EEDQ (2-ethoxy-1 ,2-dihydroquinoline-1-carboxylic acid ethyl ester) is added at 0°C to 10.96 g (33.2 mmol) of the title compound of Example 18a and 18.87 g (33.2 mmol) of 1-perfluorooctylsulfonyl-piperazine (produced according to DE 19603033) in 80 ml of tetrahydrofuran, and it is stirred overnight at room temperature. It is evaporated to the dry state in a vacuum and chromatographed on silica gel (mobile solvent: dichloromethane/methanol =20:1).
Yield: 30.93 g (93% of theory) of a colorless solid.
Elementary analysis:
Cld: C39.61 H2.89 F35.66 N6.19 S 3.54
Fond: C39.68 H2.74 F35.81 N6.13 S3.40 e) L-Glutamic acid-N-bis(2-hydroxyethyl)-amide-5-[1 -(4-perfluorooctylsulfonyl)-piperazine]- amide
Ammonia gas is introduced at 0°C for one hour into a solution that consists of 30.24 g (30.22 mmol) of the title compound of Example 18b in 200 ml of ethanol. It then is stirred for 4 hours at 0°C. It is evaporated to the dry state, and the residue is absorptively precipitated from
® va The solid is filtered off, and it is dried in a vacuum (50°C).
Yield: 26.55 g (97% of theory) of an amorphous solid.
Elementary analysis:
Cld: C41.12 H2.89 F35.66 N6.19 S3.54
Fnd: C41.15 H2.83 F35.78 N6.28 S3.71 f) N-[1,4,7-Tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecane- 1 0-(pentanoyl-3-aza-4-oxo- 5-methyl-5-y1)]-L-glutamic acid-N-bis(2-hydroxyethyl)-amide-5-[1-(4-perfluorooctylsulfonyl)- piperazine]-amide, Gd complex 211.96 g (24.25 mmol) of the title compound of Example 18e, 2.79 g (24.25 mmol) of N- hydroxysuccinimide, 2.12 g (50 mmol) of lithium chloride and 15.27 g (24.25 mmol) of 1,4,7- tris(carboxylatomethyl)-10-[(3-aza-4-oxo-5-methyl-5-yl)]-pentanoic acid]-1,4,7,10- tetraazacyclododecane, Gd complex, are dissolved in 200 ml of dimethyl sulfoxide while being heated slightly. At 10°C, 8.25 g (40 mmol) of N,N-dicyclohexylcarbodiimide is added, and it then is stirred overnight at room temperature. The solution is poured into 3000 ml of acetone and stirred for 10 minutes. The precipitated solid is filtered off and then purified by chromatography (silica gel RP-18, mobile solvent: gradient that consists of water/ethanol/acetonitrile).
Yield: 27.43 g (81% of theory) of a colorless solid.
Water content: 11.0%
Elementary analysis (relative to anhydrous substance):
Cld: C34.41 H3.83 F23.13 N9.03 $2.30 Gd 11.26
Fnd: C3434 H3.98 F23.29 N9.19 S2.15 Gd 11.07
® 3 19 a) N-Trifluoroacetyl-L-glutamic acid-5-benzylester-N-dimethyl-bis(1,1 -dihydroxymethyl)-amide 8.25 g (40 mmol) of N,N-dicyclohexylcarbodiimide is added at 0°C to a solution that consists of 8.03 g (24.08 mmol) of the title compound of Example 18a, 3.98 g (24.08 mmol) of dimethyl-bis(1,1-dihydroxymethyl)-amine and 2.77 g (24.08 mmol) of N-hydroxysuccinimide, dissolved in 150 ml of dimethylformamide. It is stirred for 3 hours at 0°C, then overnight at room temperature. Precipitated urea is filtered out, the filtrate is evaporated to the dry state in a vacuum and chromatographed on silica gel (mobile solvent: dichloromethane/ethanol = 20:1).
Yield: 110.53 g (91% of theory) of a viscous oil.
Elementary analysis:
Cld: C 50.00 H5.66 F11.86 N 7.18
Fnd: C 50.17 H5.82 F11.80 N 7.15 b) N-Trifluoroacetyl-L-glutamic acid-5-benzyl ester-[1-(4-perfluorooctylsulfonyl)-piperazine]- amide 25.05 g (52.15 mmol) of the title compound of Example 19a is dissolved in 500 ml of ethanol, and 6 g of palladium catalyst (10% Pd/C) is added. It is hydrogenated at room temperature. Catalyst is filtered out, and the filtrate is evaporated to the dry state in a vacuum.
Yield: 20.36 g (quantitative) of a colorless solid.
Elementary analysis:
Cld: C 40.00 H5.42 F14.60 N 7.18
Fnd: C 40.10 H5.53 F 14.69 N 7.28
73 8200371947 ® Cc) LF" glutamic acid-N-dimethyl-bis(1,1-dihydroxymethyl)-amide-5-[1-(4- perfluorooctyisulfonyl)piperazine]-amide 16.42 g (66.4 mmol) of EEDQ (2-ethoxy-1.2-dihydroquinoline-1-carboxylic acid ethyl ester) is added at 0°C to 12.96 g (33.2 mmol) of the title compound of Example 19b and 18.87 g (33.2 mmol) of 1-perfluorooctylsulfonyl-piperazine (produced according to DE 19603033) in 800 ml of tetrahydrofuran, and it is stirred overnight at room temperature. It is evaporated to the dry state in a vacuum and chromatographed on silica gel (mobile solvent: dichloromethane/methanol = 20:1).
Yield: 28.42 g (91% of theory) of a colorless solid.
Elementary analysis:
Cld: C31.93 H3.00 F40.40 N 5.96 S3.41
Fnd: C 32.08 H2.94 F40.57 N5.88 S3.31 d) L-Glutamic acid-N-[dimethyl-bis(1,1-dihydroxymethyl)]-amide-5-[(1-4- : perfluorooctylsulfonyl)-piperazine]-amide -
Ammonia gas is introduced at 0°C for one hour into a solution that consists of 28.41 g (30.2 mmol) of the title compound of Example 19¢ in 200 ml of ethanol. It then is stirred for 4 hours at 0°C. Tt is evaporated to the dry state, and the residue is absorptively precipitated from water. The solid is filtered off and dried in a vacuum (50°C).
Yield: 24.74 g (97% of theory) of an amorphous solid.
Elementary analysis:
Cld: C32.71 H3.46 F38.24 N6.63 S3.80
Fnd: C 32.75 H3.33 F38.38 N6.68 S3.81
14 ~ 8200371947 ® e) ® 4.7-Tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecane-10-(pentanoyl-3-aza-4- 0x0-3-methyl-3-yl)]-L-glutamic acid-N-[dimethyl-bis(1,] -dihydroxymethy!)-amide]-5-[1-(4- perfluorooctylsulfonyl)-piperazine]-amide, Gd complex 20.48 g (24.25 mmol) of the title compound of Example 19d, 2.79 g (24.25 mmol) of N- hydroxysuccinimide, 2.12 g (30 mmol) of lithium chloride and 15.27 g (24.25 mmol) of 1,4,7- tris(carboxylatomethyl)-10-[(3-aza-4-ox0-5-methyl-5-yl)]-pentanoic acid]-1,4.7,1 0- tetraazacyclododecane, Gd complex, are dissolved in 200 ml of dimethyl sulfoxide while being heated slightly. At 10°C, 8.25 g (40 mmol) of N,N-dicyclohexyl-carbodiimide is added, and it © then is stirred overnight at room temperature. The solution is poured into 3000 ml of acetone and stirred for 10 minutes. The precipitated solid is filtered off and then purified by chromatography (silica gel RP-18, mobile solvent: gradient that consists of water/ethanol/acetonitrile).
Yield: 29.05 g (83% of theory) of a colorless solid.
Water content: 11.0%
Elementary analysis (relative to anhydrous substance):
Cld: C34.12 H3.91 F22.38 N 8.73 S$2.22 Gd 10.90
Fnd: C 34.24 H3.98 F22.39 N 8.69 S2.15 Gd 10.87
Example 20 a) N-Trifluoromethylacetyl-L-glutamic acid-5-benzylester-{1 (4-perfluorooctylsulfonyl)- piperazine]-amide 16.42 g (66.4 mmol) of EEDQ (2-ethoxy-1,2-dihydroquinoline-1-carboxylic acid ethyl ester) is added at 0°C to 11.06 g (33.2 mmol) of the title compound of Example 18a and 18.87 g (33.2 mmol) of 1-perfluorooctylsulfonyl-piperazine (produced according to DE 19603033) in 80 ml of tetrahydrofuran, and it is stirred overnight at room temperature. It is evaporated to the dry state in a vacuum and chromatographed on silica gel (mobile solvent: dichloromethane/methanol = 20:1).
~ 8400371947 ® ®. 27.28 g (93% of theory) of a colorless solid.
Elementary analysis:
Cld: C35.35 H2.40 F43.01 N4.76 S3.63
Fnd: C35.48 H2.51 F42.87 N4.73 S3.50 b) N-Trifluoroacetyl-L-glutamic acid-5-[1-[4-perfluorooctylsulfonyl)-piperazine]-amide 21.92 g (52.15 mmol) of the title compound of Example 18a is dissolved in 500 ml of ethanol, and 3 g of palladium catalyst (10% Pd/C) is added. It is hydrogenated at room temperature. Catalyst is filtered out, and the filtrate is evaporated to the dry state in a vacuum.
Yield: 41.37 g (quantitative) of a colorless solid.
Elementary analysis:
Cid: C28.76 H 1.91 F 47.89 N 5.30 S4.04
Fnd: C 28.84 H2.03 F47.79 N 5.28 S4.19 ¢) N-Trifluoroacetyl-L-glutamic acid-N-bis(2-hydroxyethyl)-amide-5-[1-(4-perfluorooctyl- sulfonyl)-piperazine]-amide 8.25 g (40 mmol) of N,N-dicyclohexylcarbodiimide is added at 0°C to a solution that consists of 24.9 g (24.08 mmol) of the title compound of Example 18a, 2.53 g (24.08 mmol) of diethanolamine and 2.77 g (24.08 mmol) of N-hydroxysuccinimide, dissolved in 150 mi of dimethylformamide. It is stirred for 3 hours at 0°C, then overnight at room temperature.
Precipitated urea is filtered out, the filtrate is evaporated to the dry state in a vacuum and chromatographed on silica gel (mobile solvent = dichloromethane/ethanol = 20:1). : Yield: 9.11 g (90% of theory) of a viscous oil.
® ® analysis:
Cid: C31.37 H2.75 F43.15 N 6.36 S3.64
Fnd: C 31.22 H2.61 F43.30 N6.25 S3.81 d) L-Glutamic acid-N-bis(2-hydroxyethyl)-amide-5-[ 1-(4-perfluorooctylsulfonyl)-piperazine]- amide
Ammonia gas is introduced at 0°C for one hour into a solution that consists of 26.61 g (30.22 mmol) of the title compound of Example 18c in 200 ml of ethanol. It then is stirred for 4 hours at 0°C. It is evaporated to the dry state, and the residue is absorptively precipitated from water. The solid is filtered off and dried in a vacuum (50°C).
Yield: 23.93 g (97% of theory) of an amorphous solid.
Elementary analysis:
Cld: C 30.89 H3.09 F39.56 N 6.86 S3.93
Fnd: C 30.75 H3.13 F39.78 N 6.75 S 3.81 e) N-[1,4,7-Tris(carboxylatomethyl)-1,4,7,1 0-tetraazacyclododecane-10-(pentanoyl-3-aza-4-0xo- 5-methyl-5-yl)]-L-glutamic acid-N-bis(2-hydroxyethyl)-amide-5-[1 -(4-perfluorooctylsulfonyl)- piperazine}-amide, Gd complex 16.43 g (24.25 mmol) of the title compound of Example 20d, 2.79 g (24.25 mmol) of N- hydroxysuccinimide, 2.12 g (50 mmol) of lithium chloride and 15.27 g (24.25 mmol) of 1,4,7- tris(carboxylatomethyl)-1 0-[(3-aza-4-oxo-5-methyl-5-yl)]-pentanoic acid]-1 ,4,7,10- tetraazacyclododecane, Gd complex, are dissolved in 200 ml of dimethy! sulfoxide while being heated slightly. At 10°C, 8.25 g (40 mmol) of N,N-dicyclohexylcarbodiimide is added, and it then is stirred overnight at room temperature. The solution is poured into 3000 ml of acetone and stirred for 10 minutes. The precipitated solid is filtered off and then purified by chromatography (silica gel RP-18, mobile solvent: gradient that consists of water/ethanol/acetonitrile).
N 8400371947 ® Q.. 28.10 g (83% of theory) of a colorless solid.
Water content: 11.0%
Elementary analysis (relative to anhydrous substance):
Cld: C34.41 H3.83 F23.13 N9.03 S2.30 Gd 11.26
Fnd: C 34.44 H4.98 F23.19 N 8.89 S2.15 Gd 11.17
Example 21 a) N-Trifluoroacetyl-glutamic acid-5-benzylester-[ 1-(4-perfluorooctylsulfonyl)-piperazine]- amide 16.42 g (66.4 mmol) of EEDQ (2-ethoxy-1,2-dihydroquinoline-1-carboxylic acid ethyl ester) is added at 0°C to 11.06 g (33.2 mmol) of the title compound of Example 18a and 18.87 g (33.2 mmol) of 1-perfluorooctylsulfonyl-piperazine (produced according to DE 19603033) in 80 ml of tetrahydrofuran, and it is stirred overnight at room temperature. It is evaporated to the dry state in a vacuum and chromatographed on silica gel (mobile solvent: dichloromethane/methanol =20:1).
Yield: 27.28 g (93% of theory) of a colorless solid.
Elementary analysis: .
Cld: C 35.35 H2.40 F43.01 N4.76 S3.63
Fnd: C 35.48 H?2.54 F42.87 N4.73 S3.40 b) N-Trifluoroacetyl-L-glutamic acid-3-{1 _{4-perfluorooctylsulfonyl)-piperazine]-amide 21.92 g (52.15 mmol) of the title compound of Example 21a is dissolved in 500 ml of ethanol, and 3 g of palladium catalyst (10% Pd/C) is added. It is hydrogenated at room temperature. Catalyst is filtered out, and the filtrate is evaporated to the dry state in a vacuum.
Yield: 41.37 g (quantitative) of a colorless solid. :
- ~ 8200371947
Q.. analysis:
Cld: C28.76 H 1.91 F47.89 N 5.30 S4.04
Fnd: C 28.84 H 1.81 F47.79 N528 S4.16
Example 22
Organ distribution (including tumor and lymph node concentration) after intravenous administration of the contrast medium according to the invention from Example 3 in prostate- cancer-carrying rats.
After intravenous administration of 100 umol of total gadolinium/kg of body weight of the title compound of Example 3 in rats (Cop-inbreeding Dunning R3327 MAT-Lu prostate cancer i.m.-implanted 12 days earlier), the metal content in various organs, in tumors and in lymph nodes (pooled as mesenteral and peripheral lymph nodes) was determined 10 minutes, 1 and 24 hours after administration (MW + SD, n = 3).
_ Title Compound of Example 3
Gd- % Dosis pro Gesamigewebe oo | Konzemtrationfpmol] ~~} 10min p.i. | 1h [ 23n pi. 10min p.i. hp. 24h p.i, 0.5. i
Cober [197.2 | B13 =] 1 | 721 8 [S78] =] Liza = om
Miz ~~ [184[+[S8 [161+ 3 | 16i [= 18/025] =]007]023]« 001025/+ 001 ee HH IR EE 523 = 007 [0.18 =] 001
Niere [358] +88 |38aj= 41] 202 =1"18 [170] =| 039200 = 0.21 1138/7007
Lunge 344] x | 95 (321! =T 6 [6 S19 [7.30 =] 033 [1.27 [= 0.05 0,56] =] 0.063
Herz 177]£146 151 =| 7 | 65 = 12040 =| 011 EN ESSN CAL = 003
Gehirn 6 =| 5 16x] 3. 5 |= ©0|009]=|002][070 [= 002003 + 000
Senin IRA A TLL 3 SRN. B 942002 [070 12 ole [Pao = VY
Muskei™ 41 £|12|40 =| #13 |z 2 ]012] =] 004008 |x 001003’ 001
Tumor B= | 32 [12]= 10] 00 [= © 0.07 | 0.40 |» 0.12 [0.6 £ [042
Femur 81 |+|10[84[=] 5] 33 [= 1]050]=]006}050|=+ 002026 «]0,01 mes. LK "| 85] + | 40 [760] = 5 [77 =] 7 [0171 =[ 00% | 0.10 |= 001 [008] [0.4] periph. LK [715] «127 |1867= 6 [108 = 6 03 £/003)018]+ 003j011[][002)
Magen 190 «26931, 3 48 x8 047 | =| 0,16 | 050 . = 0,06 EE 0,03 gentieery ff | | | I iL
Darm (entleert) |145 + | 37 [130] 7 (101 |= 121248 |=] 056 | 185 |=} 0.27 £ 018
Biut* [821 x |137|534|=| 12 169 | = 16 [3518] =| 7.43 [3053] = 1.05 [9.58] + 1,02
Restkérper NE - ak — 108 [= 7 TE] - - |=} - : : s
Harn 0-24 h le] ~3160 |2 19] ~- }-] - —- |-1 - [883 + 236 : : doe fed J 8
Focces 0-24 h —~ g ~ [881 RE] ERE EEE REE 1] ol i dal vi ol
ST 5
SE JE TE LL loa *Semi Blivhg KGW 1 ; | To Ty “nT Gowebesiiaual v. reshian Urierschanirkouskal 11 HR HE i 1 = Summe Organe 10 und €C mir PL ohne Restores! | IE : 1 _ [Key to Table:]
Gd-Konzentration [pmol/l] = Gd-concentration [pmol/l] % Dosis pro Gesamtgewebe = % dose per total tissue
Leber = liver
Milz = spleen
Pankreas = pancreas
Niere = kidney
Lunge = lung
Herz = heart
® cer brain
Muskel = muscle”
Tumor = tumor
Femur = femur mes. LK = mes. LK
Periph. LK = periph. LK
Magen (entleert) = Stomach (emptied)
Darm (entleert) = intestine (emptied)
Blut’ = blood”
Restkdrper = remainder of the body
Harn 0-24 h = Urine 0-24 hours
Faeces 0-24 h = Feces 0-24 hours
Summe der Organe = The sum total of all of the organs
Bilanz = balance "58 ml Blut/kg KGW = 58 ml of blood/kg of body weight “nur Gewebealiquot v. rechten Unterschenkelmuskel = only tissue sample from right lower leg muscle "*Summe Organe 10 und 60 min p.i. ohne Restkdrper = the sum total of all of the organs at 10 and 60 min. p.i., less the remainder of the body
Claims (35)
1. Perfluoroalkyl-containing complexes with polar radicals of general formula I (R};- G — (Z-Rgla (I) (R)g in which Re is a perfluorinated, straight-chain or branched carbon chain with the formula -CnF2qE, in which E represents a terminal fluorine, chlorine, bromine, iodine or hydrogen atom, and n stands for numbers 4-30, K stands for a metal complex of general formula II, oo R*00C | v ~ © : COOR" (11) in which . R' means a hydrogen atom or a metal ion equivalent of atomic numbers 21-29, 31- 33, 37-39, 42-44, 49 or 57-83, provided that at least two R! stand for metal ion equivalents, R? and R’, independently of one another, represent hydrogen, C1-C7-alkyl, benzyl, phenyl, -CH,0H or -CH,OCH3, and U represents -CsHs-O-CHz-0-, -(CH2)1-5-w, a phenylene group, -CH,-NHCO-CHa- CH(CH2COOH)-CsHs-w-, -CsHs-(OCH2CH2)o-1-, N(CH2COOH)-CH-o or a Ci- : C12-alkylene group or a C7-C12-CsHs-O group that is optionally interrupted by one
® or more oxygen atoms, 1 to 3 -NHCO groups or 1- to 3 -CONH groups and/or is substituted with 1 to 3 -(CHz)o-sCOOH groups, whereby w stands for the binding site to -CO-, or of general formula III A ! / NTN coor 0 JY Ria ROOC™ / p.
MS COCR? {I1I) in which R' has the above-mentioned meaning, R* represents hydrogen or a metal ion equivalent that is mentioned under R', and U' represents -CsHs-O-CHa-0-, whereby @ means the binding site to -CO- or of general formula IV a JN ji \ —N N-~ rR'coc” / Tr © COOR? (IV) in which R' and R* have the above-mentioned meaning or of general formula V Aor VB
- 848UUS/ 1947 ( N-Coor® . MN ROOC™ / NN y~—COOR? “MN coor? (V A) - ~~ COOR? G ( ~COOR’ IN LT aad Od / AN No CC OR? <1" ~—~COOR" (V B) in which R' has the above-mentioned meaning, or of general formula VI RIO0C—,~ “N LC O0— R'O0OC—" ~—COOR" (VI) in which R' has the above-mentioned meaning, or of general formula VII R'00C— 2
N .. R'OOC—" uw RO OC— ROOC—" . (VII) in which R' has the above-mentioned meaning, and U' represents -CsHs-O-CHa-0-, whereby ® means the binding site to -CO-, and in radical K, optionally present free acid groups optionally can be present as salts of organic y ~~ B2003/71947 _— bases or amino acids or amino acid amides, G represents a radical that is functionalized in at least three places and that is selected from radicals a) to ) below (a) H c N= (CH, WiC CO —wat Y NH { p (b) H ¥ + CO-C—(CH)rNw- p NH ¢ o {c) o CN \ Bp ve—N N— Y MY a {(d) SINT N \ a N N—an Y a 3 p
® (a) ® ki CO ~~ SN fasm—onN N= H H (£) H HH EL an— NN —{CH,)};C—N—-CO-C—(CH,};N a B H aH | a © NH Lo i E B (g) TN TN i N I" 3 3 o Y B () Y “CO-(CHg PHCO™ Bg: 0 Bow COOH (HCO T NH I) } 15 whereby a means the binding site of G to complex K, B is the binding site of G to radical R, and y represents the binding site of G to radical Z, Z stands for STN - ¥— Nl___~ N—SO5 c y-C(O)CH20(CHz)2-€, whereby v represents the binding site of Z to radical G, and £ means the binding site of Z to perfluorinated radical Ry,
® ®, represents a polar radical selected from complexes K of general formulas II to VII, whereby R' here means a hydrogen atom or a metal ion equivalent of atomic numbers 20-29, 31-33, 37-39, 42-44 49 or 57-83, and radicals R’, R’ rR’, U and U' have the above-indicated meaning, whereby for the case that G represents radical (¢) or (d) and R represents a complex that is selected from general formulas II and V, R must not be identical to radical K of general formula [, if Z stands for §-C(O)CH20(CHz)z-¢, or the folic acid radical or R means a carbon chain with 2-30 C atoms that is bonded via -CO- or SO2- or a direct bond to radical G, in a straight line or branched, saturated or unsaturated, optionally interrupted by 1-10 oxygen atoms, 1-5 -NHCO groups, 1-5 -CONH groups, 1-2 sulfur atoms, 1-5 -NH groups or 1-2 phenylene groups, which optionally can be substituted with 1-2 OH groups, 1-2 NH; groups, 1-2 -COOH groups, or 1-2 -SOsH groups, or optionally substituted with 1-8 OH groups, 1-5 -COOH groups, 1-2 SOsH groups, 1-5 NH; groups, 1-5 C;-C4 alkoxy groups, and 1, m, p, independently of one another, mean the whole number 1 or 2.
2. Metal complexes according to claim 1, characterized in that metal ion equivalent R'in radical K is an element of atomic numbers 21-29, 39, 42, 44 or 57-83.
3. Metal complexes according to claim 1, wherein metal ion equivalent R' in radical K is an element of atomic numbers 27, 29, 31-33, 37-39, 43, 49, 62, 64, 70, 75 and 77.
4. Metal complexes according to one of claims 1 to 3, wherein K stands for a metal complex of general formula IL, III, VB or VII.
5. Metal complexes according to one of claims 1 to 4, wherein polar radical R has the e7 ~ 8200371947 2 of complex K.
6. Metal complexes according to claim 5, wherein as polar radical R, complexes K of general formulas II, III, VA or VII are present.
7. Metal complexes according to claim 5 or 6, wherein R' means a metal ion equivalent of atomic numbers 20, 25 or 64.
8. Metal complexes according to one of claims 1 to 4, wherein polar radical R has the following meanings: -C (0) CH:CH:SO3H -C {0Q) CH-0CE;CH,CCH,CH,CH -C (0) CH,0CH,CH,0H -C {0) CH0CHCH (OH) CH OH -C (O)CHNH~C (0) CH.CCCH -C {0O)CH;CH {OH} CH,0H ~-C (0) CH.0CH,COOH -S80,CH,CH,CCO3 -C (0) -CgHz~ {m~COOH} 2 -C {0} CH20 {CHz) 2-Csily- (m~COOH) 2 -C {0} CH20-CsHa-m—-50sH -C (OQ) CH,NHC (0) CHAAHC {O) CH0CH; COOH -C {0 ) CH;0CE,CH:CCH, COOH -C (0) CH#,0CH.CH (OH) CH,0-CHaCH,CH -C (0) CE20CH,CH (OH) CH:0CH;- CH (CH) ~-CH,0H ~-C {0} CH50:H -C {0} CH;CH;COCE -C {OCH (OH) CH {OH) CHCH -C (0) CH20[ {CHz) 20]1.5-CH3 -C{0O}CHE,0[ (CH;) 20]1-9-H -C (0) CH,0CH{CE;:0H] 2 -C {0O) CH,0OCH (CE;0CH;COOH) » -C (0) -CsH3- {m~OCHE;CCOHE) 2 ~CO-CH;0~ (CHa) 20 (CH; ) 2:0- (CH: ) 20 (CH, ) 20CH3 preferably —C(C}CH2C{ (CH2) 20] 4-CHs.
« } 82003/1947 ® ®, Metal complexes according to one of claims 1 to 4, wherein polar radical R is the folic acid radical.
10. Metal complexes according to one of claims 1 to 9, wherein G in general formula represents lysine radical (a) or (b).
11. Metal complexes according to one of claims 1 to 10, wherein U in metal complex K represents the group -CHz- or -C¢Ha-O-CHa-0, whereby o stands for the binding site to -CO-.
12. Use of metal complexes according to claim 2 for the production of contrast media for use in NMR diagnosis and x-ray diagnosis.
13. Use of metal complexes according to claim 12 for the production of contrast media for infarction and necrosis imaging.
14. Use of metal complexes according to claim 3 for the production of contrast media for use in radiodiagnosis and radiotherapy.
15. Use of metal complexes according to claim 2 for the production of contrast media for lymphography in the diagnosis of changes in the lymphatic system.
16. Use of metal complexes according to claim 2 for the production of contrast media for use in indirect lymphography.
17. Use of metal complexes according to claim 2 for the production of contrast media for use in intravenous lymphography.
18. Use of metal complexes according to claim 2 for the production of contrast media for visualizing the vascular space.
19. Use of metal complexes according to claim 2 for the production of contrast media for tumor imaging.
20. Pharmaceutical agent that contains at least one physiologically compatible compound according to claims 1 to 11, optionally with the additives that are commonly used in galenicals.
21. Process for the production of perfluoroalkyl-containing complexes with polar
~~ 8400371 89 9 4 7 wi of general formula I : (Ki1i-G — {Z-Rednm (1) {Rp in which K, G, R, Z, Ry, |, m and p have the meaning that is indicated in claim 1, wherein in a way that is known in the art, a carboxylic acid of general formula lla COOR? ON RE Re 9g A a —N | N~y~"~0H rRS00C” / A 1 AN A N 5 COCR (£1a) in which R® means a metal ion equivalent of atomic numbers 21-29, 3 1-33, 37-39, 42-44, 49 or 57-83 or a carboxyl protective group, and R?, R? and U have the above-mentioned meaning, or a carboxylic acid of general formula Illa ~ R® a 7 goer 0 rRSooc”/ ) COOR’ {(IIZa) in which R®, R’, and U' have the above-mentioned meaning or a carboxylic acid of general formula IVa
00 82003/1947 @ ® A R® NT N R2 \ a = N OH R*0oC™ J N COOR® (Iva) in which R® and R” have the above-mentioned meaning or a carboxylic acid of general formula Va or Vb ~—CQO-OH S (coo NER -N R*COC a; COORS HOOC” XN < ~COOR? (va) (Vo) in which R’ has the above-mentioned meaning or a carboxylic acid of general formula Via RI00C— 7 _—CO-OH RPooc— “~—COOR® (VIIa) in which R’ has the above-mentioned meaning or a carboxylic acid of general formula Vila R500C— 0 ON AL R™0O0C “U OH R°00C ~~ R*00C—~ (Via)
91 PCT/EP01/08500 in P. R3 and U! have the above-mentioned meanings, is reacted in optionally activated form with an amine of general formula VIII H -G- (Z-R), (VIID ®), in which G, R, Z, R;, m and p have the indicated meaning, in a coupling reaction and optionally subsequent cleavage of optionally present protective groups to form a metal complex of general formula I, or if R® has the meaning of a protective group, is reacted after cleavage of these protective groups in a subsequent step in a way that is known in the art with at least one metal oxide or metal salt of an element of atomic numbers 21-29, 31-33, 37-39, 42-44, 49 or 57-83, and then, if desired, optionally present acidic hydrogen atoms are substituted by cations of inorganic and/or organic bases, amino acid or amino acid amides.
22. A contrast medium for use in a method of NMR diagnosis or x-ray diagnosis, said contrast medium comprising metal complexes according to claim 2, and said method comprising administering said contrast medium.
23. A contrast medium for use in a method of diagnosis according to claim 22 for infarction and necrosis imaging.
24. A contrast medium for use in a method of radiodiagnosis or radiotherapy, said contrast medium comprising metal complexes according to claim 3, and said method comprising administering said contrast medium.
25. A contrast medium for use in a method of lymphography in the diagnosis of changes in the lymphatic system, said contrast medium comprising metal complexes according to claim 2, and said method comprising administering said contrast medium.
26. A contrast medium for use in a method of indirect lymphography, said contrast medium comprising metal complexes according to claim 2, and said method comprising administering said contrast medium.
27. A contrast medium for use in a method of intravenous lymphography, said AMENDED SHEET
92 PCT/EP01/08500 "2 medium comprising metal complexes according to claim 2, and said method comprising administering said contrast medium.
28. A contrast medium for use in a method of visualizing the vascular space, said contrast medium comprising metal complexes according to claim 2, and said method comprising administering said contrast medium.
29. A contrast medium for use in a method of tumor imaging, said contrast medium comprising metal complexes according to claim 2, and said method comprising administering said contrast medium.
30. A metal complex according to claim 1, substantially as herein described and illustrated.
31. Use according to any of claims 12, or 14 to 19, substantially as herein described and illustrated.
32. An agent according to claim 20, substantially as herein described and illustrated.
33. A process according to claim 21, substantially as herein described and illustrated.
34. A contrast medium for use in a method of diagnosis according to any of claims 22, or 24 to 29, substantially as herein described and illustrated.
35. A new metal complex; a new use of a metal complex according to claim 2, or a _ Dew use of a metal complex according to claim 3; a new agent; a new process for producing a compound; or a contrast medium for a new use in a method of diagnosis; substantially as herein described. AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10040858A DE10040858C2 (en) | 2000-08-11 | 2000-08-11 | Perfluoroalkyl-containing complexes with polar residues, process for their preparation and their use |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200301947B true ZA200301947B (en) | 2004-06-25 |
Family
ID=7653176
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200301947A ZA200301947B (en) | 2000-08-11 | 2003-03-10 | Complexes containing perfluoroalkyl with polar radicals, method for the production and use thereof. |
Country Status (30)
Country | Link |
---|---|
EP (1) | EP1307237B9 (en) |
JP (1) | JP2004506026A (en) |
KR (2) | KR20030022381A (en) |
CN (1) | CN1468113A (en) |
AR (1) | AR035342A1 (en) |
AT (1) | ATE359093T1 (en) |
AU (2) | AU7977701A (en) |
BG (1) | BG107541A (en) |
BR (1) | BR0113187A (en) |
CA (1) | CA2419259A1 (en) |
CZ (1) | CZ2003341A3 (en) |
DE (2) | DE10040858C2 (en) |
DK (1) | DK1307237T3 (en) |
EE (1) | EE200300060A (en) |
ES (1) | ES2284671T3 (en) |
HR (1) | HRP20030171A2 (en) |
HU (1) | HUP0300769A3 (en) |
IL (1) | IL154329A0 (en) |
MX (1) | MXPA03001286A (en) |
NO (1) | NO20030649L (en) |
NZ (1) | NZ524080A (en) |
PL (1) | PL365367A1 (en) |
PT (1) | PT1307237E (en) |
RU (1) | RU2289579C2 (en) |
SK (1) | SK286239B6 (en) |
UA (1) | UA74004C2 (en) |
UY (1) | UY26873A1 (en) |
WO (1) | WO2002013875A2 (en) |
YU (1) | YU10503A (en) |
ZA (1) | ZA200301947B (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10231799B4 (en) * | 2002-07-10 | 2006-10-05 | Schering Ag | Use of perfluoroalkyl-containing metal complexes as contrast agents in MR imaging for the presentation of intravascular thrombi |
US7344704B2 (en) | 2002-07-10 | 2008-03-18 | Schering Ag | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of intravascular thrombi |
DE102005033902B3 (en) * | 2005-07-15 | 2007-04-05 | Schering Ag | Perfluoroalkyl-containing complexes, processes for their preparation, and their use and pharmaceutical compositions containing them |
DE102005033903B4 (en) * | 2005-07-15 | 2007-08-09 | Bayer Schering Pharma Ag | Perfluoroalkyl-containing complexes, processes for their preparation, and their use and pharmaceutical compositions containing them |
EP1904462A2 (en) * | 2005-07-15 | 2008-04-02 | Bayer Schering Pharma Aktiengesellschaft | Complexes containing perfluoroalkyl, method for the production and use thereof |
DE102006049821A1 (en) * | 2006-10-18 | 2008-04-24 | Bayer Schering Pharma Aktiengesellschaft | New, well tolerated metal chelates, for use as radiodiagnostic, radiotherapeutic or NMR and X-ray diagnostic agents, contain chelator and perfluorinated polyethylene glycol residues |
DE102007015598A1 (en) * | 2007-03-29 | 2008-10-02 | Heinrich-Heine-Universität Düsseldorf | Use of fluorochemical compounds for diagnostic purposes using imaging techniques |
EP3101012A1 (en) | 2015-06-04 | 2016-12-07 | Bayer Pharma Aktiengesellschaft | New gadolinium chelate compounds for use in magnetic resonance imaging |
CA3044877A1 (en) | 2016-11-28 | 2018-05-31 | Bayer Pharma Aktiengesellschaft | High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging |
RU2681319C1 (en) * | 2017-10-27 | 2019-03-06 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский экономический университет имени Г.В. Плеханова" (ФГБОУ ВО "РЭУ им. Г.В. Плеханова") | Ultra-fibrous biopolymer material with bactericidal effect |
MX2021006024A (en) | 2018-11-23 | 2021-07-06 | Bayer Ag | Formulation of contrast media and process of preparation thereof. |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4317588C2 (en) * | 1993-05-24 | 1998-04-16 | Schering Ag | Macrocyclic metal complexes containing fluorine, process for their preparation and their use |
DE19603033A1 (en) * | 1996-01-19 | 1997-07-24 | Schering Ag | Perfluoroalkyl-containing metal complexes, processes for their preparation and their use in NMR diagnostics |
DE19608278A1 (en) * | 1996-02-23 | 1997-08-28 | Schering Ag | Pharmaceutical compositions containing perfluoroalkyl-containing metal complexes, and their use in tumor therapy and interventional radiology |
DE19729013A1 (en) * | 1997-07-03 | 1999-02-04 | Schering Ag | Oligomeric, perfluoroalkyl-containing compounds, processes for their preparation and their use in NMR diagnostics |
DE19744004C1 (en) * | 1997-09-26 | 1999-07-22 | Schering Ag | Lipophilic metal complexes for necrosis and infarct imaging |
-
2000
- 2000-08-11 DE DE10040858A patent/DE10040858C2/en not_active Expired - Fee Related
-
2001
- 2001-07-23 MX MXPA03001286A patent/MXPA03001286A/en not_active Application Discontinuation
- 2001-07-23 EE EEP200300060A patent/EE200300060A/en unknown
- 2001-07-23 BR BR0113187-7A patent/BR0113187A/en not_active IP Right Cessation
- 2001-07-23 AU AU7977701A patent/AU7977701A/en active Pending
- 2001-07-23 CA CA002419259A patent/CA2419259A1/en not_active Abandoned
- 2001-07-23 WO PCT/EP2001/008500 patent/WO2002013875A2/en active IP Right Grant
- 2001-07-23 CZ CZ2003341A patent/CZ2003341A3/en unknown
- 2001-07-23 DE DE50112336T patent/DE50112336D1/en not_active Expired - Fee Related
- 2001-07-23 JP JP2002519013A patent/JP2004506026A/en not_active Withdrawn
- 2001-07-23 HU HU0300769A patent/HUP0300769A3/en unknown
- 2001-07-23 SK SK155-2003A patent/SK286239B6/en unknown
- 2001-07-23 YU YU10503A patent/YU10503A/en unknown
- 2001-07-23 CN CNA018170765A patent/CN1468113A/en active Pending
- 2001-07-23 AU AU2001279777A patent/AU2001279777B2/en not_active Ceased
- 2001-07-23 RU RU2003105813/04A patent/RU2289579C2/en not_active IP Right Cessation
- 2001-07-23 NZ NZ524080A patent/NZ524080A/en unknown
- 2001-07-23 PL PL01365367A patent/PL365367A1/en unknown
- 2001-07-23 KR KR10-2003-7001937A patent/KR20030022381A/en not_active Application Discontinuation
- 2001-07-23 PT PT01958005T patent/PT1307237E/en unknown
- 2001-07-23 AT AT01958005T patent/ATE359093T1/en not_active IP Right Cessation
- 2001-07-23 IL IL15432901A patent/IL154329A0/en not_active IP Right Cessation
- 2001-07-23 KR KR1020087003857A patent/KR20080027397A/en not_active Application Discontinuation
- 2001-07-23 EP EP01958005A patent/EP1307237B9/en not_active Expired - Lifetime
- 2001-07-23 DK DK01958005T patent/DK1307237T3/en active
- 2001-07-23 ES ES01958005T patent/ES2284671T3/en not_active Expired - Lifetime
- 2001-07-23 UA UA2003032068A patent/UA74004C2/en unknown
- 2001-08-07 UY UY26873A patent/UY26873A1/en not_active Application Discontinuation
- 2001-08-10 AR ARP010103832A patent/AR035342A1/en unknown
-
2003
- 2003-02-07 BG BG107541A patent/BG107541A/en unknown
- 2003-02-10 NO NO20030649A patent/NO20030649L/en not_active Application Discontinuation
- 2003-03-10 HR HR20030171A patent/HRP20030171A2/en not_active Application Discontinuation
- 2003-03-10 ZA ZA200301947A patent/ZA200301947B/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0993306B1 (en) | Perfluoroalkylated oligomer compounds, process for preparing the same and their use in nmr diagnosis | |
US20070020183A1 (en) | Perfluoroalkyl-containing complexes, process for their production as well as their use | |
US6083479A (en) | Contrast media for infarction and necrosis imaging | |
AU2001289729B2 (en) | Perfluoroalkyl-containing complexes comprising sugar residues, method for producing the same and use thereof | |
US20090297454A1 (en) | Perfluoroalkyl-Containing Complexes, Process For Their Production As Well As Their Use | |
AU2001279777B2 (en) | Complexes containing perfluoroalkyl with polar radicals, method for the production and use thereof | |
US6019959A (en) | Oligomeric compounds that contain perfluoroalkyl, process for their production, and their use in NMR diagnosis | |
AU773189B2 (en) | Perfluoroalkylamide, the production thereof and the use thereof in diagnostics | |
AU2006272025A1 (en) | Complexes containing perfluoroalkyl, method for the production and use thereof | |
KR20030022387A (en) | Use of Metal Complexes Containing Perfluoroalkyl as Contrast Agents in MR-Imaging for the Representation of Plaques, Tumours and Necroses | |
US6676928B2 (en) | Perfluoroalkyl-containing complexes with polar radicals, process for their production and their use | |
US6641797B2 (en) | Perfluoroalkyl-containing complexes with sugar radicals, process for their production and their use | |
JP5475454B2 (en) | Metal chelates with perfluorinated PEG groups, methods for their formulation and use thereof | |
US6461587B1 (en) | Perfluoroalkylamides, their production and their use in diagnosis | |
US5919433A (en) | Macrocyclic metal complex carboxylic acids, their use as well as process for their production | |
US6166200A (en) | Cascade polymer complexes, process for their production and pharmaceutical agents containing said complexes |